cenb20180630

0001437749-18-015574.txt : 20180814 0001437749-18-015574.hdr.sgml : 20180814 20180814155726 ACCESSION NUMBER: 0001437749-18-015574 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 83 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180814 DATE AS OF CHANGE: 20180814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEN BIOTECH INC CENTRAL INDEX KEY: 0001653821 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55557 FILM NUMBER: 181017133 BUSINESS ADDRESS: STREET 1: 20 N REAR RD CITY: LAKESHORE STATE: A6 ZIP: N0R 1A0 BUSINESS PHONE: 226-344-0660 MAIL ADDRESS: STREET 1: 20 N REAR RD CITY: LAKESHORE STATE: A6 ZIP: N0R 1A0 10-Q 1 cenb20180630_10q.htm FORM 10-Q cenb20180630_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from ___________ to ___________

Commission File Number 000-55557

CEN BIOTECH, INC.

(Exact name of registrant as specified in its charter)

Ontario, Canada	-
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
7405 Tecumseh Road East Suite 300 Windsor, Ontario Canada	N8T 1G2
(Address of principal executive offices)	(Zip code)

(519) 419-4958

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (check one):

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [ ] (Do not check if a smaller reporting company)	Smaller reporting company [X]
Emerging growth company [x]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act): Yes [ ] No [X]

As of August 14, 2018, there were 25,388,243 shares of common stock, no par value per share (“common stock”), of the registrant outstanding.

TABLE OF CONTENTS

PART I

ITEM 1	CONSOLIDATED FINANCIAL STATEMENTS	3

ITEM 2	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	4

ITEM 3	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	9

ITEM 4	CONTROLS AND PROCEDURES	9

PART II

ITEM 1	LEGAL PROCEEDINGS	10

ITEM 1A	RISK FACTORS	10

ITEM 2	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	10

ITEM 3	DEFAULTS UPON SENIOR SECURITIES	11

ITEM 4	MINE SAFETY DISCLOSURE	11

ITEM 5	OTHER INFORMATION	11

ITEM 6	EXHIBITS	11

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). There are statements in this quarterly report that are not historical facts. These “forward-looking statements” can be identified by use of terminology such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “positioned,” “project,” “propose,” “should,” “strategy,” “will,” or any similar expressions. You should be aware that these forward-looking statements are subject to risks and uncertainties that are beyond our control. Although we believe that our assumptions underlying such forward-looking statements are reasonable, we do not guarantee our future performance, and our actual results may differ materially from those contemplated by these forward-looking statements. Our assumptions used for the purposes of the forward-looking statements made in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances, including the development of our lines of business and any products that we may manufacture or sell and our ability to raise additional funding sufficient to implement our strategy, as well as assumptions regarding Canadian and U.S. laws regarding the consumer or retail sale of marijuana products and accessories and the manufacture and distribution of such products and accessories, including zoning and banking regulations. We also assume that we will be able to raise additional capital to fund our operations while we develop a line of business to generate net revenues. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. In light of these numerous risks and uncertainties, we cannot provide any assurance that the results and events contemplated by our forward-looking statements contained in this quarterly report will in fact transpire. These forward-looking statements are not guarantees of future performance. You are cautioned to not place undue reliance on these forward-looking statements, which speak only as of their dates. We do not undertake any obligation to update or revise any forward-looking statements.

PART I

ITEM 1.

FINANCIAL STATEMENTS

Contents
	Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:

Unaudited condensed consolidated balance sheets	F-1

Unaudited condensed consolidated statements of operations	F-2

Unaudited condensed consolidated statements of shareholders’ deficit	F-3

Unaudited condensed consolidated statements of cash flows	F-4

Notes to the unaudited condensed consolidated financial statements	F-5

CEN BIOTECH, INC. AND SUBSIDIARY

Condensed Consolidated Balance Sheets

(Unaudited)

	June 30, 2018			December 31, 2017
ASSETS
Current assets
Cash and cash equivalents	$	22,004		$	84,978

Property, plant and improvements, net		1,445,816			1,445,415
Other receivables		465,120			222,562
Note receivable - related party		44,859			44,859
Advances to CEN Biotech Ukraine LLC - related party		775,328			775,328
Deferred lease expense		190,058			217,210
Intangible assets, net		6,018,177			6,230,583

Total assets	$	8,961,362		$	9,020,935
LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities
Accounts payable	$	171,805		$	104,828
Loans payable		10,117,369			9,981,883
Loans payable – related parties		1,062,090			838,923
Convertible notes payable		2,388,806			1,461,979
Convertible notes payable – related parties		1,098,000			2,210,313
Accrued interest		5,684,981			4,540,692
Accrued interest – related parties		768,997			592,901
Accrued expenses		339,977			295,874

Total current liabilities		21,632,025			20,027,393

Patent acquisition liability		620,000			5,000,000
Loans payable – related parties, less current portion		300,000			300,000
Convertible notes payable, less current portion		1,927,518			2,208,193
Convertible notes payable – related parties, less current portion		1,612,313			500,000

Total liabilities		26,091,856			28,035,586

Commitments and contingencies

Shareholders’ deficit
Common stock; unlimited authorized shares; 25,373,243 and 25,131,843 issued and outstanding as of June 30, 2018 and December 31, 2017, respectively. No par value.		-			-
Additional paid-in capital		13,974,509			9,110,041
Accumulated deficit		(31,105,003	)		(28,124,692	)
Total shareholders’ deficit		(17,130,494	)		(19,014,651	)
Total liabilities and shareholders’ deficit	$	8,961,362		$	9,020,935

See accompanying notes to financial statements.

F-1

CEN BIOTECH, INC. AND SUBSIDIARY

Condensed Consolidated Statements of Operations

(Unaudited)

	For the three months ended June 30,						For the six months ended June 30,
	2018			2017 (As restated – Note 18)			2018			2017 (As restated – Note 18)
Operating Expenses
Consulting fees	$	48,500		$	107,600		$	60,485		$	197,600
Consulting fees and payroll – related parties		45,839			83,727			77,039			83,727
Stock based compensation		179,800			-			347,200			-
General and administrative		694,595			414,160			1,136,434			788,891

Total operating expenses		968,734			605,487			1,621,158			1,070,218

Loss from operations		(968,734	)		(605,487	)		(1,621,158	)		(1,070,218	)

Other income (expense)
Interest expense		(608,670	)		(504,570	)		(1,203,173	)		(994,787	)
Interest expense – related parties		(105,292	)		(83,285	)		(209,578	)		(163,424	)
Foreign exchange gain (loss)		23,155			(30,953	)		53,598			(44,143	)

Other expense, net		(690,807	)		(618,808	)		(1,359,153	)		(1,202,354	)

Net loss	$	(1,659,541	)	$	(1,224,295	)	$	(2,980,311	)	$	(2,272,572	)

Net Loss Per Share:
Basic and diluted	$	(0.07	)	$	(0.18	)	$	(0.12	)	$	(0.33	)

Weighted Average Common Shares Outstanding
Basic and diluted		25,222,721			6,851,843			25,188,132			6,851,843

See accompanying notes to financial statements.

F-2

CEN BIOTECH, INC. AND SUBSIDIARY

Condensed Consolidated Statements of Shareholders’ Deficit

(Unaudited)

			Special
			Preferred				Common		Additional					Total
	Preferred		Shares		Common		Shares		Paid-in		Accumulated			Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Deficit

Balances, January 1, 2017		100,000	$	10		6,851,843	$	-	$	82	$	(14,044,238	)	$	(14,044,146	)

Net loss		-		-		-		-		-		(2,272,572	)		(2,272,572	)

Balances, June 30, 2017 (as restated – Note 18)		100,000	$	10		6,851,843		-	$	82	$	(16,316,810	)	$	(16,316,718	)


Balances, January 1, 2018		-	$	-		25,131,843	$	-	$	9,110,041	$	(28,124,692	)	$	(19,014,651	)

Patent acquisition liability modification		-		-		-		-		4,380,000		-			4,380,000

Stock-based compensation		-		-		20,000		-		347,200		-			347,200

Issuance of common stock – interest shares		-		-		96,400		-		59,768		-			59,768

Issuance of common stock – legal consulting		-		-		125,000		-		77,500		-			77,500

Net loss		-		-		-		-		-		(2,980,311	)		(2,980,311	)

Balances, June 30, 2018		-	$	-		25,373,243	$	-	$	13,974,509	$	(31,105,003	)	$	(17,130,494	)

See accompanying notes to financial statements.

F-3

CEN BIOTECH, INC. AND SUBSIDIARY

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Six Months Ended
	June 30, 2018			June 30, 2017 (as restated – Note 18)
Cash flows from operating activities
Net loss	$	(2,980,311	)	$	(2,272,572	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		5,038			883
Amortization		212,406			212,406
Stock-based compensation - employees		347,200			-
Stock-based compensation - others		77,500			-
Non-cash interest expense		1,170,577			962,526
Non-cash interest expense – related parties		209,576			161,971
Deferred lease expense		27,152			27,151
Foreign exchange (gain) loss		(53,598	)		44,143
Changes in operating assets and liabilities which provided (used) cash:
Other receivables		(242,558	)		(25,081	)
Accounts payable		62,580			(128,185	)
Accrued expenses		44,103			278,694

Net cash used in operating activities		(1,120,335	)		(738,064	)

Cash flows from investing activities
Advance on business acquisition		-			(250,000	)
Leasehold improvements in progress		(5,439	)		(102,645	)

Net cash used in investing activities		(5,439	)		(352,645	)

Cash flows from financing activities
Issuance of loans payable		380,000			-
Repayment of loans payable		(230,000	)		-
Issuance of loans payable - related parties		225,000			-
Issuance of convertible notes		707,800			-
Repayment of convertible notes		(20,000	)		-
Issuance of convertible notes - related parties		-			1,199,963

Net cash provided by financing activities		1,062,800			1,199,963

Net (decrease) increase in cash and cash equivalents		(62,974	)		109,254

Cash and cash equivalents, beginning of period		84,978			62,381

Cash and cash equivalents, end of period	$	22,004		$	171,635

Supplemental cash flows disclosures
Cash paid for interest	$	32,598		$	33,714

Non-cash transactions - investing and financing activities
Patent acquisition liability modification	$	4,380,000		$	-

Conversion of rents due to convertible loan	$	-		$	244,362
Accrued expense converted to convertible loans	$	-		$	831,628

See accompanying notes to financial statements.

F-4

CEN BIOTECH, INC. AND SUBSIDIARY

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(All amounts are in US dollars unless otherwise stated.)

NOTE 1 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) set forth in Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2017 and notes thereto.

There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s annual report on Form 10-K for the year ended December 31, 2017.

Loss per Share

Net loss per common share is computed pursuant to ASC 260-10-45. Basic loss per share is computed based on the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the diluted weighted average common shares outstanding, which includes the effect of potentially dilutive securities. During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of net loss per share. Diluted earnings per share is similarly computed except that the denominator includes the effect, using the treasury stock method, of unvested restricted stock and convertible notes, if including such potential shares of common stock is dilutive. For the three-months ended June 30, 2018 and 2017, and for the six-months ended June 30, 2018 and 2017, the common stock equivalents of the convertible note agreements were not included in diluted earnings per share computations because their effect was antidilutive.

NOTE 2 – GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS

The accompanying consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $31,105,003 at June 30, 2018 and had no committed source of debt or equity financing. The Company has not had any operating revenue and does not foresee any operating revenue in the near term. The Company has relied on the issuance of loans payable and convertible debt instruments to finance its expenses, including a note that is in default and is secured by the Company’s equipment, as described in Note 7, and unsecured convertible notes in default as described in Note 9. The Company will be dependent upon raising additional capital through placement of our common stock, notes or other securities in order to implement its business plan or additional borrowings, including from related parties. There can be no assurance that the Company will be successful in either situation in order to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The Company’s cash position may not be sufficient to support the Company’s daily operations or its ability to undertake any business activity that will generate net revenue.

F-5

NOTE 3 – NEW ACCOUNTING STANDARDS

Adoption of New Accounting Standards

On January 1, 2018, the Company adopted the new revenue recognition standard which requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. The Company is still in its startup phase and is not generating revenues at this time; therefore, this standard has no impact on its consolidated financial statements until revenues are generated. When revenues are generated, the Company will follow the provisions of the new standard.

In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, to mainly change the accounting for investments in equity securities and financial liabilities carried at fair value as well as to modify the presentation and disclosure requirements for financial instruments. The ASU is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted. Adoption of the ASU is retrospective with a cumulative adjustment to retained earnings or accumulated deficit as of the adoption date. The adoption of this pronouncement did not have an impact on the Company’s financial statements.

Accounting Standards Issued but Not Yet Adopted

In February 2016, the FASB issued an ASU which requires lessees to recognize lease assets and lease liabilities arising from operating leases on the balance sheet. This ASU is effective for annual and interim reporting periods beginning after December 15, 2018 using a modified retrospective approach, with early adoption permitted. The Company is currently evaluating the standard to determine the impact of its adoption on its consolidated financial statements. The Company will record a right-of-use asset and a lease liability upon adoption.

In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, to expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services for nonemployees. The ASU is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the standard to determine the impact of its adoption on its consolidated financial statements. The Company will measure these nonemployee awards at fair value upon adoption.

NOTE 4 – PROPERTY, PLANT AND IMPROVEMENTS, NET

Property, plant and improvements, net consists of the following:

	June 30, 2018			December 31, 2017

Improvements in process	$	1,436,278		$	1,430,839
Furniture and equipment		17,668			17,668
Accumulated depreciation		(8,130	)		(3,092	)

Net property, plant and improvements	$	1,445,816		$	1,445,415

Depreciation expense was $4,596 and $441 for the three-months ended June 30, 2018 and 2017, respectively, and $5,038 and $883 for the six months ended June 30, 2018 and 2017, respectively.

F-6

Improvements in process as of June 30, 2018 and December 31, 2017, consists almost entirely of improvements to leased facilities at 20 North Rear Road. These represent the capitalized costs the Company incurred in constructing the improvements. As of June 30, 2018, $166,163 of the leasehold improvements are being amortized.

At this time, the Company cannot make the final additions that will be necessary for the sites to function as growing spaces, although there are currently grow rooms outfitted and ready to grow.

NOTE 5 – ADVANCES TO CEN BIOTECH UKRAINE

At June 30, 2018 and December 31, 2017, the Company had advances of $775,328 to CEN Biotech Ukraine, a related party, (see Note 13). The advances are unsecured, non-interest bearing, and are due on demand.

NOTE 6 – INTANGIBLE ASSETS

On September 12, 2016, the Company executed an agreement to acquire assets, including a patent related to LED Lighting, from Tesla Digital, Inc., a Canadian corporation, and Stevan (Steve) Pokrajac.

Material consideration given by Company was: (a) Shares of CEN common stock equal to $5 million upon commencement of public trading (b) The transfer of real properties located at 135 North Rear Road, Lakeshore, Ontario, Canada having a fair value of $2,161,467 and 1517-1525 Ridge Road having a purchase cost (including other related disbursements) to the Company of $202,666.

The patent intangible remains in escrow in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, CEN has the rights to use the patented technology.

In addition, the Company will employ Stevan Pokrajac in connection with the development of the acquired technology with compensation equal to $200,000 per year, commencing with the start of operations.

In March 2018, the Tesla agreement was amended to replace the $5 million stock consideration commitment with commitment to issue one million registered shares of CEN common stock with a closing date of September 30, 2018. The modification of the agreement converted a fixed value of shares to a fixed number of shares. Due to the nature of this being all in equity, the liability was reduced and additional paid in capital was increased by $4,380,000 to reflect the fair value of the shares committed at the date of the amendment. This liability will be remeasured at each reporting date using the current fair value of CEN’s common shares.

Management reviews long-lived assets for impairment when circumstances indicate the carrying amount of an asset may not be recoverable based on the undiscounted cash flows of the asset. If the carrying amount of an asset may not be recoverable, a write-down to fair value is recorded. Fair values are determined based on the discounted cash flows, or external appraisals, as applicable.

The intangible assets consist of the following:

	June 30, 2018			December 31, 2017

Lighting patent	$	6,797,000		$	6,797,000
Accumulated amortization		(778,823	)		(566,417	)

Net	$	6,018,177		$	6,230,583

The lighting patent is being amortized straight-line over approximately 16 years. Expected amortization expense is $424,812 per year through 2031, with the remaining $283,216 to be amortized in 2032.

F-7

NOTE 7 – LOANS PAYABLE

Loans payable consist of the following:

	June 30, 2018		December 31, 2017
Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note is secured by the Company's equipment.	$	9,675,000	$	9,675,000

Mortgage payable to ARG & Pals, Inc., for the original amount of CAD $385,000. The mortgage bears interest at 22% per annum, with an extended maturity date of September 21, 2018.		292,369		306,883

Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.		50,000		-

Loan payable to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018		100,000		-

Total loans payable (all current)	$	10,117,369	$	9,981,883

The $9,675,000 loan in default is secured by certain equipment valued at approximately $11,000.

During the three-month period ended June 30, 2018, 26,000 common shares were issued to individuals for loans made to CEN. Accordingly, $16,120 in interest expense and additional paid-in capital was recorded. No such common shares were issued during the three-month period ended June 30, 2017.

During the six-month period ended June 30, 2018, interest in the form of 42,400 common shares were issued to individuals for loans and related loan extensions made to CEN. Accordingly, $26,288 in interest expense and additional paid-in capital was recorded.

F-8

NOTE 8 – LOANS PAYABLE – RELATED PARTIES

Loans payable – related parties consists of the following:

	June 30, 2018		December 31, 2017
Loan payable to the spouse of Bill Chaaban, President of CEN, bears an interest at 10% per annum. This is an unsecured loan with a maturity date of December 31, 2018.	$	235,590	$	237,423

Loan payable to a former director of Creative, former parent company, bears interest at 10% per annum. This is an unsecured loan with a maturity date of December 31, 2018.		601,500		601,500

Loan payable to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan with a maturity date of October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban’s spouse.		300,000		300,000

Loan payable to the spouse of Joseph Byrne, CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.		100,000		-

Loan payable to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.		75,000		-

Loan payable to Joseph Byrne, CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.		50,000		-

Total loans payable – related parties		1,362,090		1,138,923

Less current portion		1,062,090		838,923

Loans payable – related parties, less current portion	$	300,000	$	300,000

In March 2018, Bill Chaaban, President of CEN, fully assigned and transferred all rights, title, and interests in his loans and related accrued interest due from CEN to his spouse.

F-9

Attributable related party accrued interest was $303,541 and $248,100, as of June 30, 2018 and December 31, 2017, respectively. Interest expense attributable to related party loans was $43,367 and $20,992 for the three-months ended June 30, 2018 and 2017, respectively, and was $86,409 and $41,677 for the six-months ended June 30, 2018 and 2017, respectively.

During the three-month period ended June 30, 2018 interest in the form of 27,000 common shares were issued to related parties for loans and related loan extensions made to CEN. Accordingly, $16,740 in related party interest expense, as included above, and additional paid-in capital was recorded. No such common shares were issued during the three-month period ended June 30, 2017.

During the six-month period ended June 30, 2018, 54,000 common shares were issued to related parties for loans made to CEN. Accordingly, $33,480 in related party interest expense, as included above, and additional paid-in capital was recorded. No such common shares were issued during the six-month period ended June 30, 2017.

NOTE 9 – CONVERTIBLE NOTES

Convertible notes payable consist of the following:

	June 30, 2018		December 31, 2017

Convertible note payable, bearing interest at 7% per annum with conversion rights for 335,833 common shares. This is due on demand.	$	838,919	$	880,567

Convertible notes payable to multiple private investors bearing an interest at 5% annum with conversion rights for 2,150,463 common shares, maturing at various dates between September 2018 and June 2020.		3,460,205		2,789,605

Convertible notes payable in default to four unsecured private investors bearing an interest at 5% annum with conversion rights for 10,750 common shares, which matured in May and June 2018.		17,200		-

Total loans and convertible notes payable		4,316,324		3,670,172

Less current portion		2,388,806		1,461,979

Loans and convertible notes payable, less current portion	$	1,927,518	$	2,208,193

These notes may be converted at the option of the note holder at any time after registration of CEN’s common stock upon written notice by the note holder. These notes are convertible into a total of 2,497,046 common shares.

F-10

NOTE 10 – CONVERTIBLE NOTES – RELATED PARTIES

Loans and convertible notes payable – related parties consist of the following:

	June 30, 2018		December 31, 2017
Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020.	$	1,388,122	$	1,388,122

Convertible notes due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 656,250 common shares with maturity dates between September 2018 and February 2019.		1,050,000		1,050,000

Convertible note due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares with a maturity date of October 26, 2018.		48,000		48,000

Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020		224,191		224,191

Total loans and convertible notes payable		2,710,313		2,710,313

Less current portion		1,098,000		2,210,313

Loans and convertible notes payable, less current portion	$	1,612,313	$	500,000

In March 2018, Bill Chaaban, President of CEN, fully assigned and transferred all rights, title, and interests in his loans and related accrued interest due from CEN to his spouse.

Attributable related party accrued interest was $465,466 and $344,801 as of June 30, 2018 and December 31, 2017, respectively. Interest expense attributable to related party convertible notes was $61,925, and $61,026 for the three-months ended June 30, 2018 and 2017, respectively, and was $123,169 and $121,747 for the six-months ended June 30, 2018 and 2017, respectively.

F-11

NOTE 11 – INCOME TAXES

A reconciliation of the effective tax rate of the income tax benefit and the statutory income tax rates applied to the loss before income taxes is as follows for the six-months ended June 30:

	2018			2017

Income tax benefit at Canadian statutory rate		26.5	%		26.5	%
Valuation allowance		(26.5	%)		(26.5	%)

Effective income tax rate		0	%		0	%

As of June 30, 2018, the Company has net operating loss carryforwards of approximately $25,300,000 that may be available to reduce future years’ taxable income. Such carryforwards typically expire after 20 years. The Company currently has carry forwards that begin to expire in 2034. Future tax benefits which may arise as a result of these losses have not been recognized in these consolidated financial statements, because the Company believes that it is more likely than not that the carryforwards will expire unused and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The deferred tax asset and associated valuation allowance are as follows for the period ended June 30, 2018 and the year ended December 31, 2017:

	2018			2017

Deferred tax asset - net operating losses	$	6,700,000		$	5,900,000
Deferred tax asset valuation allowance		(6,700,000	)		(5,900,000	)

Net deferred tax asset	$	-		$	-

All other temporary differences are immaterial both individually and in the aggregate to the consolidated financial statements.

NOTE 12 – SHAREHOLDERS’ DEFICIT

The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have no par value.

NOTE 13 – RELATED PARTY TRANSACTIONS

The Company has received loans from several related parties, as described above in Notes 8 and 10.

There are advances of $775,328 to CEN Ukraine as of both June 30, 2018 and December 31, 2017. CEN Ukraine was founded by Bill Chaaban. Prior to December 3, 2017, Bill Chaaban directly owned 51% of CEN Ukraine. Subsequent to December 3, 2017, Mr. Chaaban directly owned 25.5% of CEN Ukraine. CEN Ukraine was founded to seek agricultural and pharmaceutical opportunities in Ukraine. Bill Chaaban personally funded the establishment and initial phases of CEN Ukraine. On December 14, 2017, the Company entered into a controlling interest purchase agreement with Bill Chaaban and another shareholder of CEN Ukraine for 51% of the outstanding equity interests of CEN Ukraine. The consideration will be paid by issuing common shares of the Company. The agreement, which is subject to certain conditions, has not closed as of August 14, 2018.

F-12

On July 12, 2017, the Company’s Shareholders elected individuals to serve as Directors on the Board. These individuals hold long-term convertible notes payable issued prior to the election. All notes payable bear interest at 5% per annum and are convertible to common shares with various maturity dates. They became related parties when they were elected.

During the three-months ended June 30, 2018 and 2017, the Company incurred payroll and consulting fees with certain Board Members and Officers totaling $45,839 and $0, respectively. During the six-months ended June 30, 2018 and 2017, the Company incurred payroll and consulting fees with certain Board Members and Officers totaling $77,039 and $83,727, respectively. As of June 30, 2018, and December 31, 2017, $62,400 and $11,986, respectively, was payable to these related parties for payroll and consulting charges.

During 2017, the Company purchased equipment from R&D Labs Canada, Inc., whose president is Bill Chaaban, in exchange for a $300,000 note payable. This equipment was then sold to CEN Ukraine for a loss of $255,141 in exchange for a $44,859 note receivable, payable in 10 equal installments through 2026. Due to the related party relationship between CEN and R&D Labs Canada, Inc. via Bill Chaaban, the loss on the transaction was considered to be an equity transaction and therefore was included as a distribution of paid-in capital within the consolidated statements of shareholders’ equity during 2017.

The Company leases 20 North Rear Road, a 10.4 acre site of land in Canada, through a sublease from a relative of the Company’s President. There are two buildings on the site – one of 27,000 square feet and one of 53,000 square feet. There is also a 4,000 square foot vault for security purposes. The Company constructed improvements to this property, including structures and equipment for growing marijuana, security fencing required for licensing as a marijuana producer, and other infrastructure.

The 20 North Rear Road lease agreement began on September 1, 2013 and required annual rent payments of CAD $339,000, including tax. At December 31, 2016, the balance sheet included accrued rent of $552,934, owed to Jamaal Shaban (“Lessor”), cousin of Bill Chaaban. Concurrently, the Lessor had fallen behind on a mortgage payable on the property. Effective January 2017, the Company entered into agreements to terminate the initial lease, enter into a convertible debt note with the Lessor’s creditor, and begin a new lease agreement for the same property. The new lease agreement calls for monthly rental payments of CAD $4,000 plus taxes for a period of five years. In exchange, the Company issued a debt of $824,446 in satisfaction of the accrued rent and future rent. The lease has been accounted for as an operating lease, and the amount of the note in excess of the accrued rent is treated as a deferred lease asset amortized over the 5-year lease. During each of the three-months ended June 30, 2018 and 2017, lease expenses of approximately $23,000 related to this agreement were recognized within general and administrative expenses. During each of the six-months ended June 30, 2018 and 2017, lease expenses of approximately $46,000 related to this agreement were recognized within general and administrative expenses.

F-13

NOTE 14 – STOCK BASED COMPENSATION

Adoption of Equity Compensation Plan

On November 29, 2017, the Board adopted the 2017 Equity Compensation Plan (the “Plan”) providing for the granting of options to purchase shares of common stock, restricted stock awards and other stock-based awards to directors, officers, employees, advisors and consultants. The Company reserved 20,000,000 shares of common stock for issuance under the Plan. The Plan is intended to provide equity incentives to persons retained by our Company.

Employment Agreements

On November 30, 2017, employment agreements were entered into with four key members of management:

•

Under the Employment Agreement with Bahige (Bill) Chaaban, President of the Company, Mr. Chaaban will receive compensation in the form of a base annual salary of $31,200 and a grant of 8,750,000 shares of restricted stock of the Company, of which 7,400,000 vested immediately and the remaining vesting ratably each month over the next 36 months.

•

Under the Employment Agreement with Joseph Byrne, Chief Executive Officer of the Company, Mr. Byrne will receive compensation in the form of a base annual salary of $31,200 and a grant of 1,250,000 shares of restricted stock of the Company, of which 325,000 vested immediately and the remaining vesting ratably each month over the next 36 months.

•

Under the Employment Agreement with Richard Boswell, Senior Executive Vice President and Chief Financial Officer of the Company, Mr. Boswell will receive compensation in the form of a base annual salary of $31,200 and a grant of 4,500,000 shares of restricted stock of the Company, of which 4,140,000 vested immediately and the remaining vesting ratably each month over the next 36 months.

•

Under the Employment Agreement with Brian Payne, Vice President of the Company, Mr. Payne will receive compensation in the form of a base annual salary of $31,200 and a grant of 750,000 shares of restricted stock of the Company, of which 300,000 vested immediately and the remaining vesting ratably each month over the next 36 months.

Equity Compensation Grants

On November 30, 2017, the Company granted a one-time equity award (“Equity Award”) of 20,000 restricted shares of the Company’s common stock pursuant to a Restricted Stock Agreement, to each of the following executives and directors of the Company: Bahige “Bill” Chaaban, Chairman of the Board and President of the Company; Joseph Byrne, Chief Executive Officer and Director; Richard Boswell, Senior Executive Vice President, Chief Financial Officer and Director; Brian Payne, Vice President and Director; Donald Strilchuck, Director; Harold Aubrey de Lavenu, Director; Alex Tarrabain, Director; and Ameen Ferris, Director. The Equity Awards vested immediately.

In addition, as part of this one-time equity award, Donald Strilchuck, Director, received an additional 1,000,000 restricted shares of the Company's common stock for security consulting services, of which 550,000 vested immediately and the remaining vesting ratably each month over the next 36 months. Other individuals received a total of 1,870,000 restricted shares of the Company's common stock for consulting services performed, of which 1,330,000 vested immediately and the remaining vesting ratably each month over the next 36 months. The expense related to the restricted stock awarded to non-employees for services rendered was recognized on the grant date.

On June 7, 2018, the Company elected Dr. Usamakh Saadikh to serve as a director of the Company. As compensation for his role as a Director, the company granted a one-time equity award of 20,000 shares of the Company’s common stock. This award vested immediately.

On June 19, 2018, the Company entered into an agreement with a law firm for the payment of its services under which the Company issued 125,000 shares of its common stock. This award vested immediately. The expense related to the restricted stock awarded to non-employees for services rendered was recognized on the grant date.

F-14

Restricted Stock Awards

The grant-date fair value of the restricted shares noted in the employment agreements and equity compensation grants sections above was $11,423,500. The grant-date fair value is calculated utilizing an enterprise valuation model as of the date the awards are granted. During 2017, 14,317,500 of these shares vested, with the remaining restricted stock units of 3,962,500 shares vesting pro-rata over the requisite service period, which is generally three years from the grant-date. In addition to the 145,000 shares that were granted and immediately vested during the six-months ended June 30, 2018, an additional 675,000 shares vested. Non-vested restricted stock awards participate in dividends and recipients are entitled to vote these restricted shares during the vesting period.

Compensation expense recognized in connection with the restricted stock awards was $179,800 and $347,200 for the three and six-months ended June 30, 2018. Legal expense, included within general and administrative, recognized in connection with the restricted stock awards was $77,500 for the three and six-months ended June 30, 2018.

Restricted stock award activity for the six-months ended June 30, 2018 is as follows:

	Number of Shares			Weighted- Average Grant Date Fair Value per Share		Weighted- Average Remaining Contractual Term (Years)
Non-vested at December 31, 2017		3,962,500		$	0.62		2.92
Granted		145,000		$	0.62
Vested		(820,000	)	$	0.62
Forfeited		-			-
Non-vested at June 30, 2018		3,287,500		$	0.62		2.50

The fair value of the restricted stock grants was based on the valuation of a third-party specialist. Unrecognized compensation expense related to restricted stock amounted to approximately $1,633,700 as of June 30, 2018. This expense will be recognized over the vesting period of the respective awards.

NOTE 15 – NET LOSS PER SHARE

During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of diluted net loss per share. Based on the Company’s application of the as-converted and treasury stock methods, all common stock equivalents were excluded from the computation of diluted earnings per share due to net losses as of June 30, 2018 and 2017. Common stock equivalents that were excluded for the three and six-months ended June 30, 2018 and 2017 are as follows:

Three-months Ended

June 30,

Six-months Ended

June 30,

2018

2017

2018

2017

Convertible debt

4,426,111

3,499,709

4,089,891

2,626,046

NOTE 16 – CONTINGENCY

In connection with the distribution by Creative of CEN’s common stock on February 29, 2016 and the Form 10 registration statement filed by CEN to register its shares of common stock under the Exchange Act, CEN received comments by the Staff of the Securities and Exchange Commission, including a letter dated May 4, 2016 in which the Staff noted that they “…continue to question the absence of Securities Act registration of the spin-off distribution”. In the event that the distribution of shares of CEN’s common stock was a distribution that required registration under the Securities Act, then the Company could be subject to enforcement action by the SEC that claims a violation of Section 5 of the Securities Act and could be subject to a private right of action for rescission or damages. Based on management’s estimate, any potential liability related to this matter would not be material.

F-15

NOTE 17 – FAIR VALUE DISCLOSURES

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.

The fair value of the Company’s financial instruments are as follows:

			Fair Value Measured at Reporting Date Using
	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At June 30, 2018:
Cash and cash equivalents	$	22,004	$	-	$	22,004	$	-	$	22,004
Other receivables	$	465,120	$	-	$	-	$	465,120	$	465,120
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC – related party	$	775,328	$	-	$	-	$	775,328	$	775,328
Loans payable	$	10,117,369	$	-	$	-	$	10,117,369	$	10,117,369
Loans payable – related parties	$	1,362,090	$	-	$	-	$	-	$	-
Convertible notes payable	$	4,316,324	$	-	$	-	$	4,585,314	$	4,585,314
Convertible notes payable – related parties	$	2,710,313	$	-	$	-	$	-	$	-

	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At December 31, 2017:
Cash and cash equivalents	$	84,978	$	-	$	84,978	$	-	$	84,978
Other receivables	$	222,562	$	-	$	-	$	222,562	$	222,562
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC – related party	$	775,328	$	-	$	-	$	775,328	$	775,328
Loans payable	$	9,981,883	$	-	$	-	$	9,981,883	$	9,981,883
Loans payable – related parties	$	1,138,923	$	-	$	-	$	-	$	-
Convertible notes payable	$	3,670,172	$	-	$	-	$	3,831,760	$	3,831,760
Convertible notes payable – related parties	$	2,710,313	$	-	$	-	$	-	$	-

F-16

The fair values of other receivables, note receivable - related party, and advances to CEN Biotech Ukraine, LLC approximates carrying value due to the terms of the instruments.

The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates.

The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates.

It is not practicable to estimate the fair value of loans payable – related parties and convertible notes payable – related parties due to their related party nature.

NOTE 18 – RESTATEMENT

As a result of the restatement of the previously issued 2016 consolidated financial statements, as further described in the Company’s annual report on Form 10-K for the year ended December 31, 2017, the January 1, 2017 accumulated deficit was increased by $654,453. Furthermore, as a result of the audit for the year ended December 31, 2017, the net loss reported for three and six-months ended June 30, 2017 has been increased (decreased) by $82,878 and ($105,754), respectively, and accumulated deficit increased by $548,700 to reflect the net correction of the errors identified in previously reported 2017 and 2016 results, primarily related to the recognition of a liability for a commitment of $5,000,000 worth of common stock to be issued in the future as consideration in the acquisition of the patent intangible described in Note 6 and related to the 2017 deferral on the recognition of rental expense related to a lease agreement. The recognition of the $5,000,000 liability in the restated 2016 results created a corresponding increase in the associated cost basis of the patent. The increase in the value recognized for the patent intangible in 2016 caused an increase in amortization expense to be taken in each subsequent period. The deferral of the rental expense as of January 1, 2017 in the restated results for the three and six-month period ended June 30, 2017 resulted in a decrease in the rental expense taken in the first six months of 2017.

In addition, as a result of the restatement of the previously issued 2016 consolidated financial statements, as further described in the Company’s annual report on Form 10-K for the year ended December 31, 2017, the January 1, 2017 balance of common stock was reduced by $3. It was also determined that the common stock was no-par and the associated amounts recorded within common stock was reclassified to additional paid-in capital.

In addition, certain reclassifications were noted related to interest expense. These had no net impact on consolidated results.

The effect on the Company's previously issued three and six-month period ended June 30, 2017 consolidated financial statements is summarized as follows:

Consolidated Balance Sheet as of June 30, 2017

	Previously Reported			Increase (Decrease)			As Restated

Deferred lease expense	$	-		$	244,362		$	244,362
Intangible assets, net		2,246,052			4,196,938			6,442,990
Patent acquisition liability		-			5,000,000			5,000,000
Accrued expenses		287,650			(3	)		287,649
Common stock		85			(85	)		-
Additional paid-in capital		10,000			(9,918	)		82
Accumulated deficit		(15,758,015	)		(548,700	)		(16,316,810	)

F-17

Consolidated Statement of Operations for the three-months ended June 30, 2017

	Previously Reported		Increase (Decrease)			As Restated

Consulting fees	$	212,326	$	(104,726	)	$	107,600
Consulting fees and payroll – related parties		-		83,727			83,727
General and administrative		310,283		103,877			414,160
Interest expense		62,825		441,745			504,570
Interest expense – related parties		525,030		(441,745	)		83,285

Consolidated Statement of Operations for the six-months ended June 30, 2017

	Previously Reported		Increase (Decrease)			As Restated

Consulting fees	$	302,327	$	(104,727	)	$	197,600
Consulting fees and payroll – related parties		-		83,727			83,727
General and administrative		873,645		(84,754	)		788,891
Interest expense		1,033,381		(38,594	)		994,787
Interest expense – related parties		124,830		38,594			163,424

NOTE 19 – SUBSEQUENT EVENT

On July 31, 2018, the Company entered into a Share Purchase Agreement with AstralENERGY Solar Manufacturing Corporation, LTD. (“AstralENERGY”) to acquire 70% of the outstanding common stock of AstralENERGY. The Company will issue an aggregate 2,500,000 shares of common stock of the Company as consideration for the acquisition. AstralENERGY is a manufacturer of architecturally designed solar panels for residential and commercial solar production and has also developed integrated multi-function LED street lighting systems. Consummation of the acquisition is subject to the completion of certain conditions specified in the agreement.

F-18

ITEM 2

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

Background and Overview

CEN Biotech, Inc. (“CEN” or the “Company”) is a Canadian holding company, incorporated in Canada on August 4, 2013 as a subsidiary of Creative Edge Nutrition, Inc. (“Creative”), a Nevada corporation. Creative separated its planned specialty pharmaceutical business located in Canada by transferring substantially all of the assets and liabilities of the planned specialty pharmaceutical business to CEN and effecting a distribution (“Spin Off Distribution”) of CEN common stock to Creative shareholders on February 29, 2016. The Spin-Off Distribution was expected to be tax free for U.S. Federal income tax purposes.

Prior to the Spin Off Distribution, CEN initially pursued the cannabis business in Canada and obtained funding to build the initial phase of its comprehensive seed-to-sale facility and applied to obtain a license in Canada to begin operating its state-of-the-art medical marijuana cultivation, processing, and distribution facility in Lakeshore, Ontario. On March 11, 2015, the Company’s application for a license to produce marijuana for medical purposes was formally rejected by Canadian regulatory authority. On February 1, 2016 the Company commenced legal action against the Attorney General of Canada in the Ontario Superior Court of Justice for damages for detrimental reliance, economic loss, and prejudgment and post judgment interest, costs of the proceeding and other relief that the court may seem just. As of August 14, 2018, the action in the Ontario Superior Court of Justice is still ongoing. After evaluating this action, the Company decided to not pursue the development of its medical marijuana business and to seek to develop and pursue other businesses that are related to the cannabis and other industries, including Light Emitting Diode (“LED”) lighting and hemp products for industrial, medical and food products that have a tetrahydrocannabinol (THC) that is below 0.3%.

We are focused on the manufacturing, production and development of products within the cannabis industry, including the LED lighting technology and hemp products. The Company intends to explore the usage of hemp, which it intends to cultivate for usage in industrial, medical and food products.

At present we are not able to estimate if or when we will be able to generate revenues. Our consolidated financial statements have been prepared assuming that we will continue as a going concern; however, given our recurring losses from operations, our independent registered public accounting firm has determined there is substantial doubt about our ability to continue as a going concern.

Subsequent Event

On July 31, 2018, the Company entered into a Share Purchase Agreement with AstralENERGY Solar Manufacturing Corporation, LTD. (“AstralENERGY”) as described in NOTE 19 – SUBSEQUENT EVENTS.

Results of Operations

We have incurred recurring losses and have not commenced revenue generating operations to date. Our expenses to date are primarily our general and administrative expenses and fees, costs and expenses related to acquisitions and operations. Our condensed consolidated financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.

The accompanying consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $31,105,003 at June 30, 2018 and had no committed source of debt or equity financing. The Company has not had any operating revenue and does not foresee any operating revenue in the near term. The Company has relied on the issuance of loans payable and convertible debt instruments to finance its expenses, including a note that is in default and is secured by the Company’s equipment and certain unsecured convertible notes payable. The Company will be dependent upon raising additional capital through placement of our common stock, notes or other securities in order to implement its business plan or additional borrowings, including from related parties. There can be no assurance that the Company will be successful in either situation in order to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The Company’s cash position may not be sufficient to support the Company’s daily operations or its ability to undertake any business activity that will generate net revenue.

Results of Operations for the Three and Six-Months Ended June 30, 2018 and 2017:

The following tables reflect our operating results for the three and six-months ended June 30, 2018 and 2017, respectively:

Operating Summary	Three-months ended June 30, 2018		Three-months ended June 30, 2017 (as restated)		Change
Revenues, net	$	-	$	-		-
Cost of Goods Sold		-		-		-
Gross Profit		-		-		-
Operating Expenses		968,734		605,487		60.0	%
Loss from Operations		968,734		605,487		60.0	%
Other Expense		690,807		618,808		11.6	%
Net Loss	$	1,659,541	$	1,224,295		35.6	%

Operating Summary	Six-months ended June 30, 2018		Six-months ended June 30, 2017 (as restated)		Change
Revenues, net	$	-	$	-		-
Cost of Goods Sold		-		-		-
Gross Profit		-		-		-
Operating Expenses		1,621,158		1,070,218		51.5	%
Loss from Operations		1,621,158		1,070,218		51.5	%
Other Expense		1,359,153		1,202,354		13.0	%
Net Loss	$	2,980,311	$	2,272,572		31.3	%

Revenue

We have not recognized revenue during the three and six-months ended June 30, 2018 and 2017, as we have not commenced revenue generating operations to date.

Operating Expenses

During the three months ended June 30, 2018, our operating expenses were $968,734 compared to $605,487 during the six months ended June 30, 2017. During the three months ended June 30, 2018, our operating expenses were comprised of salary and consulting fees of $94,339, stock-based compensation expense of $179,800, and general and administrative expenses of $694,595. By comparison, during the three months ended June 30, 2017, our operating expenses were comprised of salary and consulting fees of $191,327, and general and administrative expenses of $414,160. Expenses incurred during the three months ended June 30, 2018 compared to three months ended June 30, 2017 increased primarily due to stock-based compensation and professional fees. Professional fees generally include financial, legal and administrative contracted services.

During the six months ended June 30, 2018, our operating expenses were $1,621,158 compared to $1,070,218 during the six months ended June 30, 2017. During the six months ended June 30, 2018, our operating expenses were comprised of salary and consulting fees of $137,524, stock-based compensation expense of $347,200, and general and administrative expenses of $1,136,434. By comparison, during the six months ended June 30, 2017, our operating expenses were comprised of salary and consulting fees of $281,327, and general and administrative expenses of $788,891. Expenses incurred during the six months ended June 30, 2018 compared to six months ended June 30, 2017 increased primarily due to stock-based compensation and professional fees. Professional fees generally include financial, legal and administrative contracted services.

Other Income and Expense Items

During the three months ended June 30, 2018, our other expense items totaled $690,807 compared to $618,808 during the three months ended June 30, 2017. During the three months ended June 30, 2018, our other expense items were comprised of interest expense of $713,962 and foreign exchange gain of $23,155. By comparison, during the three months ended June 30, 2017, our other expense items were comprised of interest expense of $587,855, and foreign exchange loss of $30,953.

During the six months ended June 30, 2018, our other expense items totaled $1,359,153 compared to $1,202,354 during the six months ended June 30, 2017. During the six months ended June 30, 2018, our other expense items were comprised of interest expense of $1,412,751 and foreign exchange gain of $53,598. By comparison, during the six months ended June 30, 2017, our other expense items were comprised of interest expense of $1,158,211 and foreign exchange loss of $44,143.

Net Loss

Our net loss during the three months ended June 30, 2018 was $1,659,541 compared to a net loss of $1,224,295 during the three months ended June 30, 2017 due to the factors discussed above.

Our net loss during the six months ended June 30, 2018 was $2,980,311 compared to a net loss of $2,272,572 during the six months ended June 30, 2017 due to the factors discussed above.

Liquidity and Capital Resources

As of June 30, 2018, we had assets of $8,961,362, comprised of cash of $22,004, net property and equipment of $13,692, leasehold improvements of $1,432,124, a note receivable from a related party of $44,859, other receivables of $465,120, deferred lease expense of $190,058, an advance to CEN Biotech Ukraine, LLC, a related party, of $775,328, and net intangibles of $6,018,177. As of June 30, 2018, we had liabilities of $26,091,856 comprised of patent acquisition liability of $620,000, loans from related parties of $1,362,090, loans payable of $10,117,369, accrued interest and other expenses of $6,793,955, accounts payable of $171,805, convertible notes- related parties of $2,710,313 and convertible notes of $4,316,324.

Our indebtedness includes a patent acquisition liability of $620,000, accrued interest of $5,684,981, accrued interest to related parties of $768,997, as well as loans payable, loans payable to related parties, loans payable share interest, loans payable share interest to related parties, convertible notes and convertible notes to related parties totaling $18,506,096, with maturity dates as outlined below. We are in default of $9,675,000 of debt that is secured by certain equipment that we value at approximately $11,000. We are also in default of $17,200 of unsecured debt. We expect our operating and administrative expenses to be at least $2,400,000 annually. The convertible notes are due 2 years from issuance with notes maturing in 2018 through 2020.

Description	Maturity Date	Amount
Loan Payable	6/30/2016	$	9,675,000
Loan Payable	9/21/2018		292,369
Loan Payable – Related Party	12/31/2018		837,090
Loan Payable – Related Party	10/2/2019		300,000
Loan Payable – Share Interest	8/16/2018		150,000
Loan Payable – Share Interest – Related Party	8/16/2018		225,000
Convertible Notes	On Demand		838,919
Convertible Notes	Q2 2018		17,200
Convertible Notes	Q3 2018		508,612
Convertible Notes	Q4 2018		52,600
Convertible Notes	Q1 2019		566,475
Convertible Notes	Q2 2019		405,000
Convertible Notes	Q3 2019		791,017
Convertible Notes	Q4 2019		448,701
Convertible Notes	Q1 2020		591,800
Convertible Notes	Q2 2020		96,000
Convertible Notes Related Party	Q3 2018		100,000
Convertible Notes Related Party	Q4 2018		498,000
Convertible Notes Related Party	Q1 2019		500,000
Convertible Notes Related Party	Q3 2020		1,612,313

		$	18,506,096

We intend to fund our expenses through the issuance and sale of additional securities. We do not have any commitments from any persons to purchase any securities and there can be no assurance that we will be able to raise sufficient funds to pay our liabilities as they become due and payable.

Six Months Ended June 30, 2018 and 2017

Cash Flows from Operating Activities

We have not generated positive cash flows from operating activities. During the six months ended June 30, 2018, we used $1,120,335 in operating activities compared to $738,064 used in operating activities during the six months ended June 30, 2017. The increase between the two periods related primarily to increases in professional fees compared to the six months ended June 30, 2017.

Cash Flows from Investing Activities

Our use of cash flow for investing activities during the six months ended June 30, 2018 was $5,439 compared to the six months ended June 30, 2017 of $352,645. During the six months ended June 30, 2018, our use of cash flows for investing activities were comprised of leasehold improvements of $5,439. By comparison, during the six months ended June 30, 2017, our use of cash flows for investing activities was comprised of advances to CEN Ukraine of $250,000 and leasehold improvements of $102,645.

Cash Flows from Financing Activities

During the six months ended June 30, 2018, we received $1,312,800 by way of loans of nonconvertible promissory notes, convertible notes and share interest loans payable from investors to fund our working capital requirements. During the six months ended June 30, 2018, $230,000 of the share interest loans payable were repaid, and $20,000 of the convertible notes were repaid. During the six months ended June 30, 2017, we received $1,199,963 by way of loans of convertible notes from investors to fund our working capital requirements.

CEN has no committed source of debt or equity financing. Our Executive team and Board are seeking additional financing from their business contacts, but no assurances can be given that such financing will be obtained or, if obtained, on what terms.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K, obligations under any guarantee contracts or contingent obligations. We also have no other commitments, other than the costs of being a reporting company that will increase our operating costs or cash requirements in the future.

Jumpstart Our Business Startups Act of 2012

The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) provides that an emerging growth company can take advantage of certain exemptions from various reporting and other requirements that are applicable to public companies that are not emerging growth companies. We currently take advantage of some, but not all, of the reduced regulatory and reporting requirements that are available to us for as long as we qualify as an emerging growth company. Our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting for as long as we qualify as an emerging growth company.

Recent Accounting Pronouncements

Adoption of New Accounting Standards

On January 1, 2018, the Company adopted the new revenue recognition standard which requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. The Company is still in its startup phase and is not generating revenues at this time; therefore, this standard has no impact on its consolidated financial statements until such time as revenues are generated. When revenues are generated, the Company will follow the provisions of the new standard.

Accounting Standards Issued but Not Yet Adopted

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide the information called for by this Item.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our principal executive officer to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, the Company recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired control objectives, and we necessarily are required to apply our judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

Changes in Internal Control over Financial Reporting

There have been no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) during the last quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

The Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, does not expect that the Company’s disclosure controls and procedures or the Company’s internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of the controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.

Evaluation of disclosure and controls and procedures

As of June 30, 2018, our management conducted an assessment of the effectiveness of the Company's internal control over disclosure controls and procedures and financial reporting. In making this assessment, management followed an approach based on the framework set forth in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (known as “COSO”). In connection with management’s evaluation of the effectiveness of the Company’s internal control over financial reporting as of June 30, 2018, management determined that the Company did not maintain effective controls over the completeness, existence, accuracy and presentation and disclosure of the accounting for the acquisition of a patent and deferral on the recognition of rental expense related to a lease agreement for financial reporting, which resulted in a restatement of the previously issued June 30, 2017 condensed consolidated financial statements. Management determined that the ineffective controls over financial reporting constitute a material weakness.

Remediation of the Material Weakness in Internal Control Over Financial Reporting

We are currently working to remediate the material weakness referred to above with respect to our financial reporting. We have reviewed the design of our current review control over financial reporting, in particular, with regards to non-routine transactions such as acquisitions of intangibles, to determine appropriate improvements and implement enhanced procedures. As part of these enhanced procedures, we are outsourcing some of our accounting and oversight roles to a qualified accounting firm, and then management will execute the review process.

We believe these measures will remediate the control deficiency identified above and will strengthen our internal control over financial reporting. We currently are working with this accounting firm and are targeting to complete the implementation of the control enhancements during 2018. We will test the ongoing operating effectiveness of the new controls subsequent to implementation, and consider the material weakness remediated after the applicable remedial controls operate effectively for a sufficient period of time.

Revisions to disclosure Controls and Procedures

Management recognized the need for additional resources in the area of accounting and financial reporting controls and procedures. As a result, we have outsourced the accounting and financial reporting oversight roles to a qualified accounting firm with public company reporting expertise.

Readers are cautioned that internal control over financial reporting, no matter how well designed, has inherent limitations and may not prevent or detect misstatements. Therefore, even effective internal control over financial reporting can only provide reasonable assurance with respect to the financial statement preparation and presentation.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

From time to time, we may become party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. We are not currently a party, as plaintiff or defendant, to any legal proceedings that we believe to be material or which, individually or in the aggregate, would be expected to have a material effect on our business, financial condition or results of operation if determined adversely to us.

Item 1A. Risk Factors.

As a smaller reporting company, we are not required to provide the information called for by this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Between April 10, 2018 and June 30, 2018, CEN entered into loans and associated extension agreements with various parties. In consideration for such loans and associated extensions, CEN granted various individuals total aggregate amount of 53,000 and 96,400 unregistered shares of common stock of CEN during the three and six months ended June 30, 2018, respectively.

On June 19, 2018, the Company entered into an agreement with a law firm which included, as compensation, a grant of a one-time equity award of 125,000 shares of the Company’s common stock. This award vested immediately.

The unregistered shares of common stock were issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended and the provisions of Regulation D promulgated thereunder or in reliance on the provisions of Regulation S promulgated thereunder.

Item 3. Defaults Upon Senior Securities.

CEN has a payment default with respect to the term loan payable to Global Holdings International, LLC, in the principal amount of $9,675,000 and which bears compound interest at 15% per annum which was due on June 30, 2016. The aggregate amount due under this loan as of August 14, 2018 is $15,332,361. Interest and default interest and related fees currently accrue at approximately $524,000 per quarter. This note is secured by some of the Company's equipment which we value at approximately $11,000.

CEN has a payment default with respect to four unsecured convertible loans payable to four private investors, in the principal amount of $17,200 and which bear interest at 5% per annum which were due in May and June 2018. The aggregate amounts due under these loans as of August 14, 2018, including accrued interest, is approximately $19,000. Interest and default interest and related fees currently accrue at approximately $210 per quarter.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit No.

Description

The financial statement schedules and exhibits filed as part of this Quarterly Report on Form 10-Q are as follows:

Exhibits

Exhibit No.		Description

31.1		Certification of Chief Executive Officer pursuant to Exchange Act Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

31.2		Certification of the Chief Financial Officer pursuant to Exchange Act Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

32.2		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

101.INS		XBRL Instance*
101.SCH		XBRL Taxonomy Extension Schema*
101.CAL		XBRL Taxonomy Extension Calculation*
101.DEF		XBRL Taxonomy Extension Definition*
101.LAB		XBRL Taxonomy Extension Labels*
101.PRE		XBRL Taxonomy Extension Presentation*

___________________

* Filed herein.

** Furnished herewith.

b.	Financial Statement Schedules

None

SIGNATURES

Pursuant to the requirements of Section 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: August 14, 2018

	CEN BIOTECH, INC.

	By:	/s/ Joseph Byrne
	Name:	Joseph Byrne
	Title:	Chief Executive Officer

EX-31.1 2 ex_121615.htm EXHIBIT 31.1 ex_121615.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Joseph Byrne, Chief Executive Officer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CEN Biotech, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 14, 2018	/s/ Joseph Byrne
	Name: Joseph Byrne
	Title: Chief Executive Officer

EX-31.2 3 ex_121616.htm EXHIBIT 31.2 ex_121616.htm

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Richard Boswell, Chief Financial Officer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CEN Biotech, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 14, 2018	/s/ Richard Boswell
	Name: Richard Boswell
	Title: Chief Financial Officer

EX-32.1 4 ex_121617.htm EXHIBIT 32.1 ex_121617.htm

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of CEN Biotech, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, Joseph Byrne, Chief Executive Officer, do hereby certify, to my knowledge:

(1) The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: August 14, 2018

By:	/s/ Joseph Byrne
	Joseph Byrne
	Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to CEN Biotech, Inc. and will be retained by CEN Biotech, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 ex_121618.htm EXHIBIT 32.2 ex_121618.htm

Exhibit 32.2

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of CEN Biotech, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, Richard Boswell, Chief Financial Officer, do hereby certify, to my knowledge:

(1) The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: August 14, 2018

By:	/s/ Richard Boswell
	Richard Boswell
	Chief Financial Officer

EX-101.INS 6 cenb-20180630.xml XBRL INSTANCE DOCUMENT 831628 620000 5000000 5000000 5000000 4380000 4380000 4380000 775328 775328 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">NOTE </div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></div><div style="display: inline; font-weight: bold;"> </div><div style="display: inline; font-weight: bold;">– </div><div style="display: inline; font-weight: bold;">ADVANCES TO CEN BIOTECH UKRAINE</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>the Company had advances of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></div> to CEN Biotech Ukraine, a related party, (see Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div>). The advances are unsecured, non-interest bearing, and are due on demand.</div></div> 775328 775328 775328 775328 775328 775328 45839 83727 77039 83727 83727 83727 244362 2710313 2710313 1098000 2210313 1612313 500000 Between September 2018 and June 2020 Between September 2018 and June 2020 May and June 2018 May and June 2018 Between September 2018 and Feb 2019 Between September 2018 and Feb 2019 2000 4000 4000 3000 2000 27152 27151 200000 0.265 0.265 31200 31200 31200 31200 8750000 7400000 1250000 325000 4500000 4140000 750000 300000 11000 283216 303541 248100 465466 344801 768997 592901 166163 1362090 1138923 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">NOTE </div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></div><div style="display: inline; font-weight: bold;"> </div><div style="display: inline; font-weight: bold;">– LOANS PAYABLE – RELATED </div><div style="display: inline; font-weight: bold;">PART</div><div style="display: inline; font-weight: bold;">IES</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Loans payable – related parties consists of the following:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table border="0px" cellpadding="0pt" cellspacing="0pt" style="margin: 0pt auto 0pt 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30</div><div style="display: inline; font-weight: bold;">, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to the spouse of Bill Chaaban, President of CEN, bears an interest at 10% per annum. This is an unsecured loan with a maturity date of December 31, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">235,590</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">237,423</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to a former director of Creative, former parent company, bears interest at 10% per annum. This is an unsecured loan with a maturity date of December 31, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">601,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">601,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan with a maturity date of October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban’s spouse.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to the spouse of Joseph Byrne, CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to Joseph Byrne, CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total loans payable – related parties</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,362,090</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,138,923</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,062,090</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">838,923</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable – related parties, less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2018, </div>Bill Chaaban, President of CEN, fully assigned and transferred all rights, title, and interests in his loans and related accrued interest due from CEN to his spouse.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Attributable related party accrued interest was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$303,541</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$248,100,</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>respectively. Interest expense attributable to related party loans was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$43,367</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$20,992</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively, and was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$86,409</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$41,677</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>interest in the form of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,000</div> common shares were issued to related parties for loans and related loan extensions made to CEN. Accordingly, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16,740</div> in related party interest expense, as included above, and additional paid-in capital was recorded. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> such common shares were issued during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2017.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">54,000</div> common shares were issued to related parties for loans made to CEN. Accordingly, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$33,480</div> in related party interest expense, as included above, and additional paid-in capital was recorded. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> such common shares were issued during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2017.</div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> – CONVERTIBLE NOTES – RELATED PARTIES</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Loans and convertible notes payable – related parties consist of the following:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table border="0px" cellpadding="0pt" cellspacing="0pt" style="margin: 0pt auto 0pt 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30</div><div style="display: inline; font-weight: bold;">,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,388,122</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,388,122</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 656,250 common shares with maturity dates between September 2018 and February 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,050,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,050,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible note due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares with a maturity date of October 26, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,191</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,191</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total loans and convertible notes payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,710,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,710,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,098,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,210,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans and convertible notes payable, less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2018, </div>Bill Chaaban, President of CEN, fully assigned and transferred all rights, title, and interests in his loans and related accrued interest due from CEN to his spouse.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Attributable related party accrued interest was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$465,466</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$344,801</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>respectively. Interest expense attributable to related party convertible notes was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$61,925,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$61,026</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively, and was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$123,169</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$121,747</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">These notes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be converted at the option of the note holder at any time after registration of CEN’s common stock upon written notice by the note holder. These notes are convertible into a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,693,946</div> common shares.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div></div> 209576 161971 2161467 4380000 5000000 4380000 202666 44859 44859 44859 44859 44859 44859 339000 4000 465120 222562 0.51 0.255 225000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0px" cellpadding="0pt" cellspacing="0pt" style="margin: 0pt auto 0pt 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30</div><div style="display: inline; font-weight: bold;">,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,388,122</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,388,122</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 656,250 common shares with maturity dates between September 2018 and February 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,050,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,050,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible note due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares with a maturity date of October 26, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,191</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,191</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total loans and convertible notes payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,710,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,710,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,098,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,210,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans and convertible notes payable, less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0px" cellpadding="0pt" cellspacing="0pt" style="margin: 0pt auto 0pt 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30</div><div style="display: inline; font-weight: bold;">, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to the spouse of Bill Chaaban, President of CEN, bears an interest at 10% per annum. This is an unsecured loan with a maturity date of December 31, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">235,590</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">237,423</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to a former director of Creative, former parent company, bears interest at 10% per annum. This is an unsecured loan with a maturity date of December 31, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">601,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">601,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan with a maturity date of October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban’s spouse.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to the spouse of Joseph Byrne, CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to Joseph Byrne, CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total loans payable – related parties</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,362,090</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,138,923</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,062,090</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">838,923</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable – related parties, less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> 11423500 false --12-31 Q2 2018 2018-06-30 10-Q 0001653821 25388243 Yes Smaller Reporting Company CEN BIOTECH INC No No cenb

171805

104828

339977

295874

287650

-3

287649

552934

8130

3092

13974509

9110041

10000

-9918

212406

255141

179800

347200

4426111

3499709

4089891

2626046

8961362

9020935

2500000

0.51

0.7

22004

84978

62381

171635

22004

84978

-62974

109254

20000000

25373243

25131843

25373243

25131843

-3

-85

824446

4316324

4585314

3670172

3831760

1927518

2208193

2388806

1461979

9675000

2497046

1693946

335833

2150463

10750

867576

656250

30000

140120

385000

0.05

0.15

0.22

0.1

0.08

0.07

0.05

0.12

0.05

0.12

2016-06-30

2018-09-21

2018-08-16

2018-12-31

2019-10-02

2018-08-16

2020-08-17

2018-10-26

2020-08-17

190058

217210

244362

6700000

5900000

6700000

5900000

4596

441

5038

883

775328

62400

11986

-0.07

-0.18

-0.12

-0.33

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Loss per Share</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Net loss per common share is computed pursuant to ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45.</div> Basic loss per share is computed based on the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the diluted weighted average common shares outstanding, which includes the effect of potentially dilutive securities. During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of net loss per share. Diluted earnings per share is similarly computed except that the denominator includes the effect, using the treasury stock method, of unvested restricted stock and convertible notes, if including such potential shares of common stock is dilutive. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> and for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the common stock equivalents of the convertible note agreements were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in diluted earnings per share computations because their effect was antidilutive.</div></div></div></div></div></div></div>

-0.265

1633700

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Fair Value Measured at Reporting Date Using</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Carrying</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Amount</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 1</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 2</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 3</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At June 30, 2018:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,004</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,004</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,004</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other receivables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">465,120</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">465,120</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">465,120</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Note receivable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Advances to CEN Biotech Ukraine, LLC – related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,117,369</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,117,369</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,117,369</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable – related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,362,090</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,316,324</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,585,314</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,585,314</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable – related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,710,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Carrying</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Amount</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 1</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 2</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 3</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At December 31, 2017:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84,978</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84,978</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84,978</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other receivables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">222,562</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">222,562</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">222,562</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Note receivable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Advances to CEN Biotech Ukraine, LLC – related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,981,883</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,981,883</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,981,883</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable – related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,138,923</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,670,172</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,831,760</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,831,760</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable – related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,710,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">NOTE </div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></div><div style="display: inline; font-weight: bold;"> – FAIR VALUE DISCLOSURES</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The fair value of the Company’s financial instruments are as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Fair Value Measured at Reporting Date Using</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Carrying</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Amount</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 1</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 2</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 3</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At June 30, 2018:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,004</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,004</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,004</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other receivables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">465,120</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">465,120</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">465,120</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Note receivable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Advances to CEN Biotech Ukraine, LLC – related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,117,369</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,117,369</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,117,369</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable – related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,362,090</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,316,324</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,585,314</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,585,314</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable – related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,710,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" margin: 0pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Carrying</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Amount</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 1</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 2</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 3</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At December 31, 2017:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84,978</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84,978</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84,978</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other receivables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">222,562</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">222,562</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">222,562</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Note receivable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Advances to CEN Biotech Ukraine, LLC – related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,981,883</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,981,883</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,981,883</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable – related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,138,923</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,670,172</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,831,760</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,831,760</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable – related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,710,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The fair values of other receivables, note receivable - related party, and advances to CEN Biotech Ukraine, LLC approximates carrying value due to the terms of the instruments.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">It is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> practicable to estimate the fair value of loans payable – related parties and convertible notes payable – related parties due to their related party nature.</div></div>

P16Y

778823

566417

424812

6797000

6018177

6230583

23155

-30953

53598

-44143

53598

-44143

694595

414160

1136434

788891

310283

103877

873645

-84754

62580

-128185

44103

278694

242558

25081

6018177

6230583

2246052

4196938

6442990

608670

504570

1203173

994787

62825

441745

1033381

-38594

43367

20992

86409

41677

61925

61026

123169

121747

105292

83285

209578

163424

525030

-441745

124830

38594

32598

33714

5684981

4540692

77500

48500

107600

60485

197600

212326

-104726

302327

-104727

23000

46000

77500

P5Y

26091856

28035586

8961362

9020935

21632025

20027393

10117369

9981883

10117369

9981883

465120

222562

235590

237423

601500

300000

100000

75000

50000

1362090

1138923

1388122

1050000

48000

224191

2710313

838919

880567

3460205

2789605

17200

4316324

3670172

1062090

838923

1098000

2210313

2388806

1461979

300000

1612313

500000

1927518

2208193

1062800

1199963

-5439

-352645

-1120335

-738064

82878

-105754

-1659541

-1224295

-2980311

-2272572

-2980311

-690807

-618808

-1359153

-1202354

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number of</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted-</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average Grant</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Date Fair Value</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">per Share</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted-</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contractual</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Term</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Years)</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 49%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-vested at December 31, 2017</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,962,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">145,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(820,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Non-vested at June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,287,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.50</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </table></div>

1062090

838923

300000

44859

968734

605487

1621158

1070218

-968734

-605487

-1621158

-1070218

25300000

1170577

962526

5439

102645

250000

775328

707800

1199963

380000

1436278

1430839

17668

1445816

1445415

45839

77039

83727

20000

230000

-31105003

-654453

-548700

-28124692

-15758015

-16316810

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three-months Ended</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six-months Ended</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible debt</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,426,111</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,499,709</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,089,891</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,626,046</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0px" cellpadding="0pt" cellspacing="0pt" style="margin: 0pt auto 0pt 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30</div><div style="display: inline; font-weight: bold;">, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible note payable, bearing interest at 7% per annum with conversion rights for 335,833 common shares. This is due on demand.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">838,919</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">880,567</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable to multiple private investors bearing an interest at 5% annum with conversion rights for 2,150,463 common shares, maturing at various dates between September 2018 and June 2020.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,460,205</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,789,605</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable in default to four unsecured private investors bearing an interest at 5% annum with conversion rights for 10,750 common shares, which matured in May and June 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,200</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total loans and convertible notes payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,316,324</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,670,172</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,388,806</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,461,979</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans and convertible notes payable, less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,927,518</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,208,193</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax asset - net operating losses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,700,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,900,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax asset valuation allowance</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,700,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,900,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Net deferred tax asset</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;">$</div></td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">- </div></div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;">$</div></td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">- </div></div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax benefit at Canadian statutory rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(26.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(26.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Effective income tax rate</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"> </div></td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">0</div></div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><div style="display: inline; font-weight: bold;">%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"> </div></td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">0</div></div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><div style="display: inline; font-weight: bold;">%</div></td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Previously</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Reported</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Increase</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Decrease)</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">As Restated</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 46%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred lease expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">244,362</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">244,362</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets, net</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,246,052</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,196,938</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,442,990</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Patent acquisition liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,000,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,000,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">287,650</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">287,649</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(85</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Additional paid-in capital</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(9,918</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accumulated deficit</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,758,015</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(548,700</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16,316,810</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Previously</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Reported</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Increase</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Decrease)</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">As Restated</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 46%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Consulting fees</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">212,326</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(104,726</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">107,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Consulting fees and payroll – related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">83,727</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">83,727</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">310,283</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">103,877</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">414,160</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">62,825</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">441,745</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">504,570</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest expense – related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">525,030</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(441,745</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">83,285</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Previously</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Reported</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Increase</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Decrease)</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">As Restated</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 46%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Consulting fees</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">302,327</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(104,727</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">197,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Consulting fees and payroll – related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">83,727</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">83,727</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">873,645</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(84,754</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">788,891</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,033,381</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(38,594</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">994,787</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest expense – related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">124,830</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38,594</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">163,424</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0px" cellpadding="0pt" cellspacing="0pt" style="margin: 0pt auto 0pt 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June </div><div style="display: inline; font-weight: bold;">3</div><div style="display: inline; font-weight: bold;">0</div><div style="display: inline; font-weight: bold;">,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note is secured by the Company's equipment.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,675,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,675,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Mortgage payable to ARG & Pals, Inc., for the original amount of CAD $385,000. The mortgage bears interest at 22% per annum, with an extended maturity date of September 21, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">292,369</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">306,883</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total loans payable (all current)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,117,369</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,981,883</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

179800

347200

P3Y

20000

1000000

1870000

145000

0.62

3962500

3287500

0.62

P2Y335D

P2Y182D

550000

1330000

14317500

145000

675000

820000

0.62

100000

6851843

100000

6851843

25131843

25373243

9675000

292369

306883

50000

100000

10117369

9981883

125000

26000

42400

27000

54000

96400

1000000

20000

77500

16120

26288

16740

33480

59768

5000000

347200

-17130494

-19014651

-14044238

-14044146

-16316810

-16316718

9110041

-28124692

13974509

-31105003

25222721

6851843

25188132

6851843

xbrli:shares xbrli:pure iso4217:USD iso4217:CAD iso4217:USD xbrli:shares 0001653821 cenb:LeaseArrangement20NorthRearRoadMember 2013-09-01 2013-09-01 0001653821 2016-01-01 2016-12-31 0001653821 2016-09-12 2016-09-12 0001653821 us-gaap:PatentedTechnologyMember 2016-09-12 2016-09-12 0001653821 cenb:LeaseArrangement20NorthRearRoadMember 2017-01-01 2017-01-31 0001653821 2017-01-01 2017-06-30 0001653821 us-gaap:ConvertibleDebtSecuritiesMember 2017-01-01 2017-06-30 0001653821 cenb:RelatedPartiesLendersMember 2017-01-01 2017-06-30 0001653821 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember 2017-01-01 2017-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember 2017-01-01 2017-06-30 0001653821 cenb:ConsultingFeesMember cenb:BoardMembersAndOfficersMember 2017-01-01 2017-06-30 0001653821 srt:RestatementAdjustmentMember 2017-01-01 2017-06-30 0001653821 srt:ScenarioPreviouslyReportedMember 2017-01-01 2017-06-30 0001653821 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-06-30 0001653821 us-gaap:CommonStockMember 2017-01-01 2017-06-30 0001653821 us-gaap:PreferredStockMember 2017-01-01 2017-06-30 0001653821 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0001653821 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0001653821 cenb:ConvertiblePayable1Member us-gaap:ConvertibleDebtMember 2017-01-01 2017-12-31 0001653821 cenb:ConvertiblePayable2Member 2017-01-01 2017-12-31 0001653821 cenb:ConvertiblePayable3Member 2017-01-01 2017-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:BillChaabanPresidentOfCenBiotechMember 2017-01-01 2017-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2017-01-01 2017-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorHaroldAubreyDeLavenuMember 2017-01-01 2017-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:JosephByrneMember 2017-01-01 2017-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:JeffThomasFormerDirectorOfCreativeEdgeMember 2017-01-01 2017-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:MrChaabansSpouseMember 2017-01-01 2017-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:RDLabsCanadaIncMember 2017-01-01 2017-12-31 0001653821 cenb:EquipmentSoldToRelatedPartyInExchangeForNoteReceivableMember cenb:CENBiotechUkraineMember 2017-01-01 2017-12-31 0001653821 cenb:CENBiotechUkraineMember 2017-01-01 2017-12-31 0001653821 cenb:ShortTermLoanPayableToGlobalHoldingsInternationalLLCMember 2017-01-01 2017-12-31 0001653821 cenb:ShortTermMortgagePayableToARGPalsIncMember 2017-01-01 2017-12-31 0001653821 2017-04-01 2017-06-30 0001653821 us-gaap:ConvertibleDebtSecuritiesMember 2017-04-01 2017-06-30 0001653821 cenb:IndividualLendersMember 2017-04-01 2017-06-30 0001653821 cenb:RelatedPartiesLendersMember 2017-04-01 2017-06-30 0001653821 us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember 2017-04-01 2017-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember 2017-04-01 2017-06-30 0001653821 cenb:ConsultingFeesMember cenb:BoardMembersAndOfficersMember 2017-04-01 2017-06-30 0001653821 srt:RestatementAdjustmentMember 2017-04-01 2017-06-30 0001653821 srt:ScenarioPreviouslyReportedMember 2017-04-01 2017-06-30 0001653821 cenb:RestrictedSharesIssuedForConsultingServicesPerfomedMember 2017-11-30 2017-11-30 0001653821 cenb:RestrictedSharesIssuedForSecurityConsultingServicesMember cenb:DirectorDonaldStrilchuckMember 2017-11-30 2017-11-30 0001653821 us-gaap:RestrictedStockMember us-gaap:PresidentMember 2017-11-30 2017-11-30 0001653821 us-gaap:ChiefExecutiveOfficerMember 2017-11-30 2017-11-30 0001653821 us-gaap:ChiefExecutiveOfficerMember cenb:VestedImmediatelyMember 2017-11-30 2017-11-30 0001653821 us-gaap:PresidentMember 2017-11-30 2017-11-30 0001653821 us-gaap:PresidentMember cenb:VestedImmediatelyMember 2017-11-30 2017-11-30 0001653821 cenb:SeniorExecutiveVicePresidentAndChiefFinancialOfficerMember 2017-11-30 2017-11-30 0001653821 cenb:SeniorExecutiveVicePresidentAndChiefFinancialOfficerMember cenb:VestedImmediatelyMember 2017-11-30 2017-11-30 0001653821 us-gaap:VicePresidentMember 2017-11-30 2017-11-30 0001653821 us-gaap:VicePresidentMember cenb:VestedImmediatelyMember 2017-11-30 2017-11-30 0001653821 2018-01-01 2018-03-31 0001653821 2018-01-01 2018-06-30 0001653821 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-06-30 0001653821 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0001653821 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0001653821 us-gaap:RestrictedStockMember cenb:VestingImmediatelyUponGrantMember 2018-01-01 2018-06-30 0001653821 us-gaap:RestrictedStockMember cenb:VestingInPeriodsSubsequentToGrantMember 2018-01-01 2018-06-30 0001653821 cenb:IndividualLendersMember 2018-01-01 2018-06-30 0001653821 cenb:RelatedPartiesLendersMember 2018-01-01 2018-06-30 0001653821 cenb:ConvertiblePayable1Member us-gaap:ConvertibleDebtMember 2018-01-01 2018-06-30 0001653821 cenb:ConvertiblePayable2Member 2018-01-01 2018-06-30 0001653821 cenb:ConvertiblePayable3Member 2018-01-01 2018-06-30 0001653821 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0001653821 us-gaap:ConvertibleDebtMember 2018-01-01 2018-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember 2018-01-01 2018-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:BillChaabanPresidentOfCenBiotechMember 2018-01-01 2018-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2018-01-01 2018-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorHaroldAubreyDeLavenuMember 2018-01-01 2018-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:JosephByrneMember 2018-01-01 2018-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember 2018-01-01 2018-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:JeffThomasFormerDirectorOfCreativeEdgeMember 2018-01-01 2018-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:MrChaabansSpouseMember 2018-01-01 2018-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:RDLabsCanadaIncMember 2018-01-01 2018-06-30 0001653821 cenb:ConsultingFeesMember cenb:BoardMembersAndOfficersMember 2018-01-01 2018-06-30 0001653821 cenb:CENBiotechUkraineMember 2018-01-01 2018-06-30 0001653821 cenb:DirectorAlexTarrabainMember 2018-01-01 2018-06-30 0001653821 cenb:JosephByrneMember 2018-01-01 2018-06-30 0001653821 cenb:SpouseOfJosephByrneCEOOfCENBiotechMember 2018-01-01 2018-06-30 0001653821 cenb:SecondShortTermLoanPayableToAnIndividualMember 2018-01-01 2018-06-30 0001653821 cenb:ShortTermLoanPayableToAnIndividualMember 2018-01-01 2018-06-30 0001653821 cenb:ShortTermLoanPayableToGlobalHoldingsInternationalLLCMember 2018-01-01 2018-06-30 0001653821 cenb:ShortTermMortgagePayableToARGPalsIncMember 2018-01-01 2018-06-30 0001653821 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0001653821 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001653821 us-gaap:PreferredStockMember 2018-01-01 2018-06-30 0001653821 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001653821 cenb:TeslaDigitalMember us-gaap:ScenarioForecastMember 2018-03-01 2018-09-30 0001653821 2018-04-01 2018-06-30 0001653821 us-gaap:ConvertibleDebtSecuritiesMember 2018-04-01 2018-06-30 0001653821 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0001653821 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0001653821 cenb:IndividualLendersMember 2018-04-01 2018-06-30 0001653821 cenb:RelatedPartiesLendersMember 2018-04-01 2018-06-30 0001653821 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember 2018-04-01 2018-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember 2018-04-01 2018-06-30 0001653821 cenb:ConsultingFeesMember cenb:BoardMembersAndOfficersMember 2018-04-01 2018-06-30 0001653821 us-gaap:DirectorMember 2018-06-07 2018-06-07 0001653821 2018-06-19 2018-06-19 0001653821 cenb:AstralENERGYMember us-gaap:SubsequentEventMember 2018-07-31 2018-07-31 0001653821 2016-12-31 0001653821 cenb:ErrorCorrectionRelatedToEquityTransactionForSharesIssuedForServicesNotProvidedMember 2016-12-31 0001653821 cenb:LeaseArrangement20NorthRearRoadMember 2016-12-31 0001653821 srt:RestatementAdjustmentMember 2016-12-31 0001653821 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001653821 us-gaap:CommonStockMember 2016-12-31 0001653821 us-gaap:PreferredStockMember 2016-12-31 0001653821 us-gaap:RetainedEarningsMember 2016-12-31 0001653821 cenb:LeaseArrangement20NorthRearRoadMember 2017-01-31 0001653821 cenb:ConvertibleDebtIssuedToLessorsCreditorMember 2017-01-31 0001653821 2017-06-30 0001653821 srt:RestatementAdjustmentMember 2017-06-30 0001653821 srt:ScenarioPreviouslyReportedMember 2017-06-30 0001653821 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001653821 us-gaap:CommonStockMember 2017-06-30 0001653821 us-gaap:PreferredStockMember 2017-06-30 0001653821 us-gaap:RetainedEarningsMember 2017-06-30 0001653821 cenb:LongTermConvertibleNotesPayableToMultiplePrivateInvestorsMember 2017-07-12 0001653821 cenb:EquityCompensation2017PlanMember 2017-11-29 0001653821 cenb:CENBiotechUkraineMember 2017-12-02 0001653821 cenb:CENBiotechUkraineMember 2017-12-03 0001653821 2017-12-31 0001653821 us-gaap:RestrictedStockMember 2017-12-31 0001653821 us-gaap:RestrictedStockMember cenb:VestingProrateOverTheRequisiteServicePeriodMember 2017-12-31 0001653821 cenb:ConvertiblePayable1Member us-gaap:ConvertibleDebtMember 2017-12-31 0001653821 cenb:ConvertiblePayable2Member 2017-12-31 0001653821 cenb:ConvertiblePayable2Member us-gaap:ConvertibleDebtMember 2017-12-31 0001653821 cenb:ConvertiblePayable3Member 2017-12-31 0001653821 cenb:ConvertiblePayable3Member us-gaap:ConvertibleDebtMember 2017-12-31 0001653821 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0001653821 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0001653821 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0001653821 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0001653821 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0001653821 us-gaap:ConvertibleDebtMember 2017-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember 2017-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:BillChaabanPresidentOfCenBiotechMember 2017-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2017-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorHaroldAubreyDeLavenuMember 2017-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:JosephByrneMember 2017-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember 2017-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2017-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:JeffThomasFormerDirectorOfCreativeEdgeMember 2017-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:JosephByrneMember 2017-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:MrChaabansSpouseMember 2017-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:RDLabsCanadaIncMember 2017-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:SpouseOfJosephByrneCEOOfCENBiotechMember 2017-12-31 0001653821 cenb:FurnitureAndEquipmentMember 2017-12-31 0001653821 cenb:ImprovementsInProcessMember 2017-12-31 0001653821 cenb:ConsultingFeesMember cenb:BoardMembersAndOfficersMember 2017-12-31 0001653821 cenb:EquipmentSoldToRelatedPartyInExchangeForNoteReceivableMember cenb:CENBiotechUkraineMember 2017-12-31 0001653821 cenb:PurchasedEquipmentInExchangeForNotePayableMember cenb:RDLabsCanadaIncMember 2017-12-31 0001653821 cenb:CENBiotechUkraineMember 2017-12-31 0001653821 cenb:SecondShortTermLoanPayableToAnIndividualMember 2017-12-31 0001653821 cenb:ShortTermLoanPayableToAnIndividualMember 2017-12-31 0001653821 cenb:ShortTermLoanPayableToGlobalHoldingsInternationalLLCMember 2017-12-31 0001653821 cenb:ShortTermMortgagePayableToARGPalsIncMember 2017-12-31 0001653821 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001653821 us-gaap:CommonStockMember 2017-12-31 0001653821 us-gaap:PreferredStockMember 2017-12-31 0001653821 us-gaap:RetainedEarningsMember 2017-12-31 0001653821 2018-06-30 0001653821 us-gaap:RestrictedStockMember 2018-06-30 0001653821 cenb:ConvertiblePayable1Member us-gaap:ConvertibleDebtMember 2018-06-30 0001653821 cenb:ConvertiblePayable2Member 2018-06-30 0001653821 cenb:ConvertiblePayable2Member us-gaap:ConvertibleDebtMember 2018-06-30 0001653821 cenb:ConvertiblePayable3Member 2018-06-30 0001653821 cenb:ConvertiblePayable3Member us-gaap:ConvertibleDebtMember 2018-06-30 0001653821 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0001653821 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0001653821 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0001653821 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0001653821 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-06-30 0001653821 us-gaap:ConvertibleDebtMember 2018-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember 2018-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:BillChaabanPresidentOfCenBiotechMember 2018-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2018-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorHaroldAubreyDeLavenuMember 2018-06-30 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:JosephByrneMember 2018-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember 2018-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2018-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:JeffThomasFormerDirectorOfCreativeEdgeMember 2018-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:JosephByrneMember 2018-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:MrChaabansSpouseMember 2018-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:RDLabsCanadaIncMember 2018-06-30 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:SpouseOfJosephByrneCEOOfCENBiotechMember 2018-06-30 0001653821 cenb:FurnitureAndEquipmentMember 2018-06-30 0001653821 cenb:ImprovementsInProcessMember 2018-06-30 0001653821 cenb:ConsultingFeesMember cenb:BoardMembersAndOfficersMember 2018-06-30 0001653821 cenb:CENBiotechUkraineMember 2018-06-30 0001653821 cenb:DirectorAlexTarrabainMember 2018-06-30 0001653821 cenb:JosephByrneMember 2018-06-30 0001653821 cenb:SpouseOfJosephByrneCEOOfCENBiotechMember 2018-06-30 0001653821 cenb:SecondShortTermLoanPayableToAnIndividualMember 2018-06-30 0001653821 cenb:ShortTermLoanPayableToAnIndividualMember 2018-06-30 0001653821 cenb:ShortTermLoanPayableToGlobalHoldingsInternationalLLCMember 2018-06-30 0001653821 cenb:ShortTermMortgagePayableToARGPalsIncMember 2018-06-30 0001653821 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001653821 us-gaap:CommonStockMember 2018-06-30 0001653821 us-gaap:PreferredStockMember 2018-06-30 0001653821 us-gaap:RetainedEarningsMember 2018-06-30 0001653821 cenb:AstralENERGYMember us-gaap:SubsequentEventMember 2018-07-31 0001653821 2018-08-14 0001653821 cenb:CENBiotechUkraineMember us-gaap:ScenarioForecastMember 2018-12-31

EX-101.SCH 7 cenb-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Going Concern Uncertainty / Management Plans link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - New Accounting Standards link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Property, Plant and Improvements, Net link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Advances to CEN Biotech Ukraine link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Intangible Assets link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Loans Payable link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Convertible Notes link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Shareholders' Deficit link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Stock Based Compensation link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 16 - Contingency link:calculationLink link:definitionLink link:presentationLink 022 - Document - Note 17 - Fair Value Disclosures link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 18 - Restatement link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 19 - Subsequent Event link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 4 - Property, Plant and Improvements, Net (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 6 - Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 7 - Loans Payable (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 9 - Convertible Notes (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 11 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 14 - Stock Based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 17 - Fair Value Disclosures (Tables) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 18 - Restatement (Tables) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 2 - Going Concern Uncertainty / Management Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 4 - Property, Plant and Improvements, Net (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 5 - Advances to CEN Biotech Ukraine (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 6 - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 6 - Intangible Assets - Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 7 - Loans Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 7 - Loans Payable - Loans Payable (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 9 - Convertible Notes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 9 - Convertible Notes - Convertible Notes (Details) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 11 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 11 - Income Taxes - Reconciliation of Effective Tax Rate (Details) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 11 - Income Taxes - Deferred Tax Assets (Details) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note 12 - Shareholders' Deficit (Details Textual) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 14 - Stock Based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note 14 - Stock Based Compensation - Restricted Stock Award Activity (Details) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note 17 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note 18 - Restatement (Details Textual) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note 18 - Restatement - Effect on Previously Issued Consolidated Financial Statements (Details) link:calculationLink link:definitionLink link:presentationLink 066 - Disclosure - Note 19 - Subsequent Event (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 cenb-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 cenb-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 cenb-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual cenb_NoncashOrPartNoncashAcquisitionNoncashConsiderationCarryingValueOfPropertiesToBeTransferred Noncash or Part Noncash Acquisition, Noncash Consideration, Carrying Value of Properties to be Transferred The carrying value of the properties to be transferred in a noncash or part noncash consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Significant Accounting Policies Note 4 - Property, Plant and Improvements, Net Note 6 - Intangible Assets Note 7 - Loans Payable Note 8 - Loans Payable - Related Parties us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Note 9 - Convertible Notes Note 10 - Convertible Notes - Related Parties Note 11 - Income Taxes Stock-based compensation - others Note 14 - Stock Based Compensation Income Tax Disclosure [Text Block] Note 15 - Net Loss Per Share Note 17 - Fair Value Disclosures Note 18 - Restatement Stock based compensation Stock-based compensation - employees Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 6 - Intangible Assets - Intangible Assets (Details) Note 7 - Loans Payable - Loans Payable (Details) Title of Individual [Axis] Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals) us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life Relationship to Entity [Domain] Note 8 - Loans Payable - Related Parties - Loans Payable to Related Parties (Details) Note 8 - Loans Payable - Related Parties - Loans Payable to Related Parties (Details) (Parentheticals) Earnings Per Share, Policy [Policy Text Block] Note 9 - Convertible Notes - Convertible Notes (Details) Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals) Note 10 - Convertible Notes - Related Parties - Convertible Notes Payable to Related Parties (Details) Non-vested, weighted average remaining contractual term (Year) Note 10 - Convertible Notes - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals) Amortization Note 11 - Income Taxes - Reconciliation of Effective Tax Rate (Details) Note 11 - Income Taxes - Deferred Tax Assets (Details) Note 14 - Stock Based Compensation - Restricted Stock Award Activity (Details) Operating Expenses Note 15 - Net Loss Per Share - Antidilutive Securities (Details) Note 17 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) Note 18 - Restatement - Effect on Previously Issued Consolidated Financial Statements (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Granted, weithged average grant date fair value (in dollars per share) us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Business Acquisition, Percentage of Voting Interests Acquired Vested, weithged average grant date fair value (in dollars per share) Forfeited, weithged average grant date fair value (in dollars per share) Schedule of Finite-Lived Intangible Assets [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Non-vested, weithged average grant date fair value (in dollars per share) Non-vested, weithged average grant date fair value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited, number of share (in shares) us-gaap_LesseeOperatingLeaseTermOfContract Lessee, Operating Lease, Term of Contract us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance Non-vested, number of share (in shares) Non-vested, number of share (in shares) Depreciation Depreciation, Total Granted, number of share (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested, number of share (in shares) Intangible Assets Disclosure [Text Block] Nonvested Restricted Stock Shares Activity [Table Text Block] Less current portion us-gaap_LongTermDebtCurrent Loans payable Cash and cash equivalents us-gaap_CashAndCashEquivalentsFairValueDisclosure Stockholders' Equity Note Disclosure [Text Block] Convertible notes payable Common stock Common stock; unlimited authorized shares; 25,373,243 and 25,131,843 issued and outstanding as of June 30, 2018 and December 31, 2017, respectively. No par value. Common Stock, Value, Issued, Ending Balance Adjustments to reconcile net loss to net cash used in operating activities: Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Common Stock, No Par Value Restatement [Axis] Accrued expenses Accrued expenses Restatement [Domain] Previously Reported [Member] us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance Restatement Adjustment [Member] us-gaap_DeferredTaxAssetsValuationAllowance Deferred tax asset valuation allowance us-gaap_InterestPayableCurrent Accrued interest Accounts payable us-gaap_PaymentsForProceedsFromProductiveAssets Leasehold improvements in progress us-gaap_DeferredTaxAssetsNet Net deferred tax asset AstralENERGY [Member] Information related to AstralENERGY. cenb_LeaseholdImprovementsSubjectToAmortizationRemainingBalance Leasehold Improvements Subject to Amortization, Remaining Balance Represents the remaining balance (yet to be amortized), as of a specified date, of leasehold improvements subject to amortization. Cash paid for interest us-gaap_PolicyTextBlockAbstract Accounting Policies Convertible Payable 3 [Member] Represents the third tranche of convertible payable. Property, Plant and Equipment Disclosure [Text Block] Second Short-term Loan Payable to an Individual [Member] Represents information pertaining to a second short-term loan payable to an individual. Property, Plant and Equipment [Table Text Block] Vesting in Periods Subsequent to Grant [Member] Represents information pertaining to awards that vest in periods subsequent to the period in which they are granted. Vesting Immediately Upon Grant [Member] Represents information pertaining to awards that vest immediately upon grant. Portion at Fair Value Measurement [Member] [Default] Estimate of Fair Value Measurement [Member] Furniture and Equipment [Member] Represents the information pertaining to furniture and equipment. Measurement Basis [Axis] Improvements in Process [Member] Represents the information pertaining to the improvements in process. Fair Value, Inputs, Level 3 [Member] Foreign exchange gain (loss) Non-cash transactions - investing and financing activities Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Fair Value Hierarchy and NAV [Axis] Patent acquisition liability modification cenb_AdjustmentsToAdditionalPaidInCapitalPatentAcquisitionLiabilityModification Adjustments to Additional Paid in Capital, Patent Acquisition Liability Modification Amount of increase (decrease) to additional paid in capital (APIC) resulting from patent acquisition liability modification. Current liabilities Vesting [Axis] Patented Technology [Member] Vesting [Domain] us-gaap_Assets Total assets Supplemental cash flows disclosures Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Cash flows from operating activities Statement [Line Items] Short-term Loan Payable to an Individual [Member] Represents the information pertaining the short-term loan payable to an individual. us-gaap_DebtDefaultLongtermDebtAmount Debt Instrument, Debt Default, Amount Additional paid-in capital Additional paid-in capital Share Interest (in shares) Contractual share interest, per 30-day period, for funds borrowed under the debt agreement. Finite-Lived Intangible Assets by Major Class [Axis] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Shareholders’ deficit cenb_OperatingLeaseAnnualRent Operating Lease Annual Rent Amount of the annual rent required for operating lease. Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Adjustments for Error Corrections [Axis] us-gaap_NonoperatingIncomeExpense Other expense, net Property, Plant and Equipment, Type [Axis] Other receivables us-gaap_LoansReceivableFairValueDisclosure Adjustments for Error Correction [Domain] Property, Plant and Equipment, Type [Domain] Equity Award [Domain] Spouse of Joseph Byrne, CEO of CEN Biotech [Member] Represents the information pertaining to the spouse of Joseph Bryne, CEO of CEN Biotech. Deferred tax asset - net operating losses Current assets Fair Value Disclosures [Text Block] Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Award Type [Axis] Net loss Net Income (Loss) Attributable to Parent, Total Net loss Fair Value, by Balance Sheet Grouping [Table Text Block] us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated amortization us-gaap_FiniteLivedIntangibleAssetsNet Net Intangible assets, net Intangible assets, net Lighting patent us-gaap_FiniteLivedIntangibleAssetsGross Restricted Stock [Member] us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Commitments and contingencies us-gaap_PaymentsToFundLongtermLoansToRelatedParties Payments to Fund Long-term Loans to Related Parties us-gaap_OperatingIncomeLoss Loss from operations Convertible Debt Securities [Member] Other income (expense) us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net (decrease) increase in cash and cash equivalents Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Counterparty Name [Axis] Counterparty Name [Domain] us-gaap_DueToRelatedPartiesCurrentAndNoncurrent Due to Related Parties, Total Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation Property, plant and improvements, net Net property, plant and improvements us-gaap_PropertyPlantAndEquipmentGross Improvements in process Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Tesla Digital [Member] Represents the information pertaining to Tesla Digital. us-gaap_DueFromRelatedParties Due from Related Parties, Total Related Parties Lenders [Member] Represents the information pertaining to related-party lenders. Individual Lenders [Member] Represents the information pertaining to the individual lenders. us-gaap_AccruedRentCurrentAndNoncurrent Accrued Rent Cash flows from investing activities Retained Earnings [Member] Earnings Per Share [Text Block] Convertible Debt [Member] us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction Additional Paid-in Capital [Member] Common Stock [Member] Related Party Transactions Disclosure [Text Block] Preferred Stock [Member] us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued expenses Short-term Debt, Type [Axis] Equity Components [Axis] Short-term Debt, Type [Domain] Equity Component [Domain] Long-term Debt us-gaap_LongTermDebt Long-term Debt us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_OperatingExpenses Total operating expenses cenb_OperatingLeaseMonthlyRent Operating Lease, Monthly Rent Amount of the monthly rent required for operating lease. Other receivables Amount due from parties in nontrade transactions, classified as other, expected to be collected after one year or the normal operating cycle, if longer. General and administrative General and administrative EX-101.PRE 11 cenb-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2018	Aug. 14, 2018
Document Information [Line Items]
Entity Registrant Name	CEN BIOTECH INC
Entity Central Index Key	0001653821
Trading Symbol	cenb
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		25,388,243
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Amendment Flag	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 22,004	$ 84,978
Property, plant and improvements, net	1,445,816	1,445,415
Other receivables	465,120	222,562
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC - related party	775,328	775,328
Deferred lease expense	190,058	217,210
Intangible assets, net	6,018,177	6,230,583
Total assets	8,961,362	9,020,935
Current liabilities
Accounts payable	171,805	104,828
Loans payable	10,117,369	9,981,883
Loans payable – related parties	1,062,090	838,923
Convertible notes payable	2,388,806	1,461,979
Convertible notes payable – related parties	1,098,000	2,210,313
Accrued interest	5,684,981	4,540,692
Accrued interest – related parties	768,997	592,901
Accrued expenses	339,977	295,874
Total current liabilities	21,632,025	20,027,393
Patent acquisition liability	620,000	5,000,000
Loans payable – related parties, less current portion	300,000	300,000
Convertible notes payable, less current portion	1,927,518	2,208,193
Convertible notes payable – related parties, less current portion	1,612,313	500,000
Total liabilities	26,091,856	28,035,586
Commitments and contingencies
Shareholders’ deficit
Common stock; unlimited authorized shares; 25,373,243 and 25,131,843 issued and outstanding as of June 30, 2018 and December 31, 2017, respectively. No par value.
Additional paid-in capital	13,974,509	9,110,041
Accumulated deficit	(31,105,003)	(28,124,692)
Total shareholders’ deficit	(17,130,494)	(19,014,651)
Total liabilities and shareholders’ deficit	$ 8,961,362	$ 9,020,935

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands	Jun. 30, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares issued (in shares)	25,373,243	25,131,843
Common stock, shares outstanding (in shares)	25,373,243	25,131,843

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating Expenses
Consulting fees	$ 48,500	$ 107,600	$ 60,485	$ 197,600
Consulting fees and payroll – related parties	45,839	83,727	77,039	83,727
Stock based compensation	179,800		347,200
General and administrative	694,595	414,160	1,136,434	788,891
Total operating expenses	968,734	605,487	1,621,158	1,070,218
Loss from operations	(968,734)	(605,487)	(1,621,158)	(1,070,218)
Other income (expense)
Interest expense	(608,670)	(504,570)	(1,203,173)	(994,787)
Interest expense – related parties	(105,292)	(83,285)	(209,578)	(163,424)
Foreign exchange gain (loss)	23,155	(30,953)	53,598	(44,143)
Other expense, net	(690,807)	(618,808)	(1,359,153)	(1,202,354)
Net loss	$ (1,659,541)	$ (1,224,295)	$ (2,980,311)	$ (2,272,572)
Net Loss Per Share:
Basic and diluted (in dollars per share)	$ (0.07)	$ (0.18)	$ (0.12)	$ (0.33)
Basic and diluted (in shares)	25,222,721	6,851,843	25,188,132	6,851,843

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Dec. 31, 2016	100,000	6,851,843
Balances at Dec. 31, 2016	$ 10		$ 82	$ (14,044,238)	$ (14,044,146)
Net loss				(2,272,572)	(2,272,572)
Balances (in shares) at Jun. 30, 2017	100,000	6,851,843
Balances at Jun. 30, 2017	$ 10		82	(16,316,810)	(16,316,718)
Balances (in shares) at Dec. 31, 2017		25,131,843
Balances at Dec. 31, 2017			9,110,041	(28,124,692)	(19,014,651)
Net loss				(2,980,311)	(2,980,311)
Patent acquisition liability modification			4,380,000		4,380,000
Stock-based compensation (in shares)		20,000
Stock-based compensation			347,200		347,200
Issuance of common stock – interest shares (in shares)		96,400
Issuance of common stock – interest shares			59,768		59,768
Issuance of common stock – legal consulting (in shares)		125,000
Issuance of common stock – legal consulting			77,500		77,500
Balances (in shares) at Jun. 30, 2018		25,373,243
Balances at Jun. 30, 2018			$ 13,974,509	$ (31,105,003)	$ (17,130,494)

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities
Net loss	$ (2,980,311)	$ (2,272,572)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	5,038	883
Amortization	212,406	212,406
Stock-based compensation - employees	347,200
Stock-based compensation - others	77,500
Non-cash interest expense	1,170,577	962,526
Non-cash interest expense – related parties	209,576	161,971
Deferred lease expense	27,152	27,151
Foreign exchange (gain) loss	(53,598)	44,143
Changes in operating assets and liabilities which provided (used) cash:
Other receivables	(242,558)	(25,081)
Accounts payable	62,580	(128,185)
Accrued expenses	44,103	278,694
Net cash used in operating activities	(1,120,335)	(738,064)
Cash flows from investing activities
Advance on business acquisition		(250,000)
Leasehold improvements in progress	(5,439)	(102,645)
Net cash used in investing activities	(5,439)	(352,645)
Cash flows from financing activities
Issuance of loans payable	380,000
Repayment of loans payable	(230,000)
Issuance of loans payable - related parties	225,000
Issuance of convertible notes	707,800
Repayment of convertible notes	(20,000)
Issuance of convertible notes - related parties		1,199,963
Net cash provided by financing activities	1,062,800	1,199,963
Net (decrease) increase in cash and cash equivalents	(62,974)	109,254
Cash and cash equivalents, beginning of period	84,978	62,381
Cash and cash equivalents, end of period	22,004	171,635
Supplemental cash flows disclosures
Cash paid for interest	32,598	33,714
Non-cash transactions - investing and financing activities
Patent acquisition liability modification	4,380,000
Conversion of rents due to convertible loan		244,362
Accrued expense converted to convertible loans		$ 831,628

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE 1 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) set forth in Article 8 of Regulation S- X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2017 and notes thereto. There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s annual report on Form 10 -K for the year ended December 31, 2017. Loss per Share Net loss per common share is computed pursuant to ASC 260 - 10 - 45. Basic loss per share is computed based on the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the diluted weighted average common shares outstanding, which includes the effect of potentially dilutive securities. During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of net loss per share. Diluted earnings per share is similarly computed except that the denominator includes the effect, using the treasury stock method, of unvested restricted stock and convertible notes, if including such potential shares of common stock is dilutive. For the three -months ended June 30, 2018 and 2017, and for the six -months ended June 30, 2018 and 2017, the common stock equivalents of the convertible note agreements were not included in diluted earnings per share computations because their effect was antidilutive.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Going Concern Uncertainty / Management Plans	6 Months Ended
Note 2 - Going Concern Uncertainty / Management Plans	Jun. 30, 2018
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2 – GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS The accompanying consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $31,105,003 at June 30, 2018 and had no committed source of debt or equity financing. The Company has not had any operating revenue and does not foresee any operating revenue in the near term. The Company has relied on the issuance of loans payable and convertible debt instruments to finance its expenses, including a note that is in default and is secured by the Company’s equipment, as described in Note 7, and unsecured convertible notes in default as described in Note 9. The Company will be dependent upon raising additional capital through placement of our common stock, notes or other securities in order to implement its business plan or additional borrowings, including from related parties. There can be no assurance that the Company will be successful in either situation in order to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. The Company’s cash position may not be sufficient to support the Company’s daily operations or its ability to undertake any business activity that will generate net revenue.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 3 - New Accounting Standards	6 Months Ended
Note 3 - New Accounting Standards	Jun. 30, 2018
Notes to Financial Statements
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	NOTE 3 – NEW ACCOUNTING STANDARDS Adoption of New Accounting Standards On January 1, 2018, the Company adopted the new revenue recognition standard which requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. The Company is still in its startup phase and is not generating revenues at this time; therefore, this standard has no impact on its consolidated financial statements until revenues are generated. When revenues are generated, the Company will follow the provisions of the new standard. In January 2016, the FASB issued ASU No. 2016 - 01, Recognition and Measurement of Financial Assets and Financial Liabilities, to mainly change the accounting for investments in equity securities and financial liabilities carried at fair value as well as to modify the presentation and disclosure requirements for financial instruments. The ASU is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted. Adoption of the ASU is retrospective with a cumulative adjustment to retained earnings or accumulated deficit as of the adoption date. The adoption of this pronouncement did not have an impact on the Company’s financial statements. Accounting Standards Issued but Not Yet Adopted In February 2016, the FASB issued an ASU which requires lessees to recognize lease assets and lease liabilities arising from operating leases on the balance sheet. This ASU is effective for annual and interim reporting periods beginning after December 15, 2018 using a modified retrospective approach, with early adoption permitted. The Company is currently evaluating the standard to determine the impact of its adoption on its consolidated financial statements. The Company will record a right-of-use asset and a lease liability upon adoption. In June 2018, the FASB issued ASU No. 2018 - 07, Improvements to Nonemployee Share-Based Payment Accounting, to expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services for nonemployees. The ASU is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the standard to determine the impact of its adoption on its consolidated financial statements. The Company will measure these nonemployee awards at fair value upon adoption.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Property, Plant and Improvements, Net

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

NOTE

– PROPERTY, PLANT AND IMPROVEMENTS

, NET

Property, plant and improvements, net consists of the following:

	June 30, 2018			December 31, 2017

Improvements in process	$	1,436,278		$	1,430,839
Furniture and equipment		17,668			17,668
Accumulated depreciation		(8,130	)		(3,092	)

Net property, plant and improvements	$	1,445,816		$	1,445,415

Depreciation expense was

$4,596

and

$441

for the

three

-months ended

June 30, 2018

and

2017,

respectively, and

$5,038

and

$883

for the

six

months ended

June 30, 2018

and

2017,

respectively.

Improvements in process as of

June 30, 2018

and

December 31, 2017,

consists almost entirely of improvements to leased facilities at

North Rear Road. These represent the capitalized costs the Company incurred in constructing the improvements. As of

June 30, 2018,

$166,163

of the leasehold improvements are being amortized.

At this time, the Company cannot make the final additions that will be necessary for the sites to function as growing spaces, although there are currently grow rooms outfitted and ready to grow.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Advances to CEN Biotech Ukraine	6 Months Ended
Note 5 - Advances to CEN Biotech Ukraine	Jun. 30, 2018
Notes to Financial Statements
Advances to Related Party [Text Block]	NOTE 5 – ADVANCES TO CEN BIOTECH UKRAINE At June 30, 2018 and December 31, 2017, the Company had advances of $ 775,328 to CEN Biotech Ukraine, a related party, (see Note 13 ). The advances are unsecured, non-interest bearing, and are due on demand.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Intangible Assets Disclosure [Text Block]

NOTE

– INTANGIBLE ASSETS

September 12, 2016,

the Company executed an agreement to acquire assets, including a patent related to LED Lighting, from Tesla Digital, Inc., a Canadian corporation, and Stevan (Steve) Pokrajac.

Material consideration given by Company was: (a) Shares of CEN common stock equal to

million upon commencement of public trading (b) The transfer of real properties located at

135

North Rear Road, Lakeshore, Ontario, Canada having a fair value of

$2,161,467

and

1517

1525

Ridge Road having a purchase cost (including other related disbursements) to the Company of

$202,666.

The patent intangible remains in escrow in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, CEN has the rights to use the patented technology.

In addition, the Company will employ Stevan Pokrajac in connection with the development of the acquired technology with compensation equal to

$200,000

per year, commencing with the start of operations.

March 2018,

the Tesla agreement was amended to replace the

million stock consideration commitment with commitment to issue

one million

registered shares of CEN common stock with a closing date of

September 30, 2018.

The modification of the agreement converted a fixed value of shares to a fixed number of shares. Due to the nature of this being all in equity, the liability was reduced and additional paid in capital was increased by

$4,380,000

to reflect the fair value of the shares committed at the date of the amendment. This liability will be remeasured at each reporting date using the current fair value of CEN’s common shares.

Management reviews long-lived assets for impairment when circumstances indicate the carrying amount of an asset

may

not

be recoverable based on the undiscounted cash flows of the asset. If the carrying amount of an asset

may

not

be recoverable, a write-down to fair value is recorded. Fair values are determined based on the discounted cash flows, or external appraisals, as applicable.

The intangible assets consist of the following:

	June 30, 2018			December 31, 2017

Lighting patent	$	6,797,000		$	6,797,000
Accumulated amortization		(778,823	)		(566,417	)

Net	$	6,018,177		$	6,230,583

The lighting patent is being amortized straight-line over approximately

years. Expected amortization expense is

$424,812

per year through

2031,

with the remaining

$283,216

to be amortized in

2032.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Loans Payable

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Short-term Debt [Text Block]

NOTE

–

LOANS PAYABLE

Loans payable consist of the following:

	June 3 0 , 2018		December 31, 2017
Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note is secured by the Company's equipment.	$	9,675,000	$	9,675,000

Mortgage payable to ARG & Pals, Inc., for the original amount of CAD $385,000. The mortgage bears interest at 22% per annum, with an extended maturity date of September 21, 2018.		292,369		306,883

Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.		50,000		-

Loan payable to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018		100,000		-

Total loans payable (all current)	$	10,117,369	$	9,981,883

The

$9,675,000

loan in default is secured by certain equipment valued at approximately

$11,000.

During the

three

-month period ended

June 30, 2018,

26,000

common shares were issued to individuals for loans made to CEN. Accordingly,

$16,120

in interest expense and additional paid-in capital was recorded.

such common shares were issued during the

three

-month period ended

June 30, 2017.

During the

six

-month period ended

June 30, 2018,

interest in the form of

42,400

common shares were issued to individuals for loans and related loan extensions made to CEN. Accordingly,

$26,288

in interest expense and additional paid-in capital was recorded.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Loans Payable - Related Parties

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Loans Payable to Related Party [Text Block]

NOTE

– LOANS PAYABLE – RELATED

PART

IES

Loans payable – related parties consists of the following:

	June 30 , 2018		December 31, 2017
Loan payable to the spouse of Bill Chaaban, President of CEN, bears an interest at 10% per annum. This is an unsecured loan with a maturity date of December 31, 2018.	$	235,590	$	237,423

Loan payable to a former director of Creative, former parent company, bears interest at 10% per annum. This is an unsecured loan with a maturity date of December 31, 2018.		601,500		601,500

Loan payable to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan with a maturity date of October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban’s spouse.		300,000		300,000

Loan payable to the spouse of Joseph Byrne, CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.		100,000		-

Loan payable to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.		75,000		-

Loan payable to Joseph Byrne, CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.		50,000		-

Total loans payable – related parties		1,362,090		1,138,923

Less current portion		1,062,090		838,923

Loans payable – related parties, less current portion	$	300,000	$	300,000

March 2018,

Bill Chaaban, President of CEN, fully assigned and transferred all rights, title, and interests in his loans and related accrued interest due from CEN to his spouse.

Attributable related party accrued interest was

$303,541

and

$248,100,

as of

June 30, 2018

and

December 31, 2017,

respectively. Interest expense attributable to related party loans was

$43,367

and

$20,992

for the

three

-months ended

June 30, 2018

and

2017,

respectively, and was

$86,409

and

$41,677

for the

six

-months ended

June 30, 2018

and

2017,

respectively.

During the

three

-month period ended

June 30, 2018

interest in the form of

27,000

common shares were issued to related parties for loans and related loan extensions made to CEN. Accordingly,

$16,740

in related party interest expense, as included above, and additional paid-in capital was recorded.

such common shares were issued during the

three

-month period ended

June 30, 2017.

During the

six

-month period ended

June 30, 2018,

54,000

common shares were issued to related parties for loans made to CEN. Accordingly,

$33,480

in related party interest expense, as included above, and additional paid-in capital was recorded.

such common shares were issued during the

six

-month period ended

June 30, 2017.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 9 - Convertible Notes

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Long-term Debt [Text Block]

NOTE

– CONVERTIBLE NOTES

Convertible notes payable consist of the following:

	June 30 , 2018		December 31, 2017

Convertible note payable, bearing interest at 7% per annum with conversion rights for 335,833 common shares. This is due on demand.	$	838,919	$	880,567

Convertible notes payable to multiple private investors bearing an interest at 5% annum with conversion rights for 2,150,463 common shares, maturing at various dates between September 2018 and June 2020.		3,460,205		2,789,605

Convertible notes payable in default to four unsecured private investors bearing an interest at 5% annum with conversion rights for 10,750 common shares, which matured in May and June 2018.		17,200		-

Total loans and convertible notes payable		4,316,324		3,670,172

Less current portion		2,388,806		1,461,979

Loans and convertible notes payable, less current portion	$	1,927,518	$	2,208,193

These notes

may

be converted at the option of the note holder at any time after registration of CEN’s common stock upon written notice by the note holder. These notes are convertible into a total of

2,497,046

common shares.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 10 - Convertible Notes - Related Parties

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Long-term Convertible Notes Related Party [Text Block]

NOTE

– CONVERTIBLE NOTES – RELATED PARTIES

Loans and convertible notes payable – related parties consist of the following:

	June 30 , 2018		December 31, 2017
Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020.	$	1,388,122	$	1,388,122

Convertible notes due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 656,250 common shares with maturity dates between September 2018 and February 2019.		1,050,000		1,050,000

Convertible note due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares with a maturity date of October 26, 2018.		48,000		48,000

Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020		224,191		224,191

Total loans and convertible notes payable		2,710,313		2,710,313

Less current portion		1,098,000		2,210,313

Loans and convertible notes payable, less current portion	$	1,612,313	$	500,000

March 2018,

Bill Chaaban, President of CEN, fully assigned and transferred all rights, title, and interests in his loans and related accrued interest due from CEN to his spouse.

Attributable related party accrued interest was

$465,466

and

$344,801

as of

June 30, 2018

and

December 31, 2017,

respectively. Interest expense attributable to related party convertible notes was

$61,925,

and

$61,026

for the

three

-months ended

June 30, 2018

and

2017,

respectively, and was

$123,169

and

$121,747

for the

six

-months ended

June 30, 2018

and

2017,

respectively.

These notes

may

be converted at the option of the note holder at any time after registration of CEN’s common stock upon written notice by the note holder. These notes are convertible into a total of

1,693,946

common shares.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 11 - Income Taxes

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Income Tax Disclosure [Text Block]

NOTE

– INCOME TAXES

A reconciliation of the effective tax rate of the income tax benefit and the statutory income tax rates applied to the loss before income taxes is as follows for the

six

-months ended

June 30:

	2018			2017

Income tax benefit at Canadian statutory rate		26.5	%		26.5	%
Valuation allowance		(26.5	%)		(26.5	%)

Effective income tax rate		0	%		0	%

As of

June 30, 2018,

the Company has net operating loss carryforwards of approximately

$25,300,000

that

may

be available to reduce future years’ taxable income. Such carryforwards typically expire after

years. The Company currently has carry forwards that begin to expire in

2034.

Future tax benefits which

may

arise as a result of these losses have

not

been recognized in these consolidated financial statements, because the Company believes that it is more likely than

not

that the carryforwards will expire unused and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The deferred tax asset and associated valuation allowance are as follows for the period ended

June 30, 2018

and the year ended

December 31, 2017:

	2018			2017

Deferred tax asset - net operating losses	$	6,700,000		$	5,900,000
Deferred tax asset valuation allowance		(6,700,000	)		(5,900,000	)

Net deferred tax asset	$	-		$	-

All other temporary differences are immaterial both individually and in the aggregate to the consolidated financial statements.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 12 - Shareholders' Deficit	6 Months Ended
Note 12 - Shareholders' Deficit	Jun. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 12 – SHAREHOLDERS’ DEFICIT The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have no par value.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 13 - Related Party Transactions	6 Months Ended
Note 13 - Related Party Transactions	Jun. 30, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 13 – RELATED PARTY TRANSACTIONS The Company has received loans from several related parties, as described above in Notes 8 and 10. There are advances of $775,328 to CEN Ukraine as of both June 30, 2018 and December 31, 2017. CEN Ukraine was founded by Bill Chaaban. Prior to December 3, 2017, Bill Chaaban directly owned 51% of CEN Ukraine. Subsequent to December 3, 2017, Mr. Chaaban directly owned 25.5% of CEN Ukraine. CEN Ukraine was founded to seek agricultural and pharmaceutical opportunities in Ukraine. Bill Chaaban personally funded the establishment and initial phases of CEN Ukraine. On December 14, 2017, the Company entered into a controlling interest purchase agreement with Bill Chaaban and another shareholder of CEN Ukraine for 51% of the outstanding equity interests of CEN Ukraine. The consideration will be paid by issuing common shares of the Company. The agreement, which is subject to certain conditions, has not closed as of August 14, 2018. On July 12, 2017, the Company’s Shareholders elected individuals to serve as Directors on the Board. These individuals hold long-term convertible notes payable issued prior to the election. All notes payable bear interest at 5% per annum and are convertible to common shares with various maturity dates. They became related parties when they were elected. During the three -months ended June 30, 2018 and 2017, the Company incurred payroll and consulting fees with certain Board Members and Officers totaling $45,839 and $0, respectively. During the six -months ended June 30, 2018 and 2017, the Company incurred payroll and consulting fees with certain Board Members and Officers totaling $77,039 and $83,727, respectively. As of June 30, 2018, and December 31, 2017, $62,400 and $11,986, respectively, was payable to these related parties for payroll and consulting charges. During 2017, the Company purchased equipment from R&D Labs Canada, Inc., whose president is Bill Chaaban, in exchange for a $300,000 note payable. This equipment was then sold to CEN Ukraine for a loss of $255,141 in exchange for a $44,859 note receivable, payable in 10 equal installments through 2026. Due to the related party relationship between CEN and R&D Labs Canada, Inc. via Bill Chaaban, the loss on the transaction was considered to be an equity transaction and therefore was included as a distribution of paid-in capital within the consolidated statements of shareholders’ equity during 2017. The Company leases 20 North Rear Road, a 10.4 acre site of land in Canada, through a sublease from a relative of the Company’s President. There are two buildings on the site – one of 27,000 square feet and one of 53,000 square feet. There is also a 4,000 square foot vault for security purposes. The Company constructed improvements to this property, including structures and equipment for growing marijuana, security fencing required for licensing as a marijuana producer, and other infrastructure. The 20 North Rear Road lease agreement began on September 1, 2013 and required annual rent payments of CAD $339,000, including tax. At December 31, 2016, the balance sheet included accrued rent of $552,934, owed to Jamaal Shaban (“Lessor”), cousin of Bill Chaaban. Concurrently, the Lessor had fallen behind on a mortgage payable on the property. Effective January 2017, the Company entered into agreements to terminate the initial lease, enter into a convertible debt note with the Lessor’s creditor, and begin a new lease agreement for the same property. The new lease agreement calls for monthly rental payments of CAD $4,000 plus taxes for a period of five years. In exchange, the Company issued a debt of $824,446 in satisfaction of the accrued rent and future rent. The lease has been accounted for as an operating lease, and the amount of the note in excess of the accrued rent is treated as a deferred lease asset amortized over the 5 -year lease. During each of the three -months ended June 30, 2018 and 2017, lease expenses of approximately $23,000 related to this agreement were recognized within general and administrative expenses. During each of the six -months ended June 30, 2018 and 2017, lease expenses of approximately $46,000 related to this agreement were recognized within general and administrative expenses.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 14 - Stock Based Compensation

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

NOTE

– STOCK BASED COMPENSATION

Adoption of Equity Compensation Plan

November 29, 2017,

the Board adopted the

2017

Equity Compensation Plan (the “Plan”) providing for the granting of options to purchase shares of common stock, restricted stock awards and other stock-based awards to directors, officers, employees, advisors and consultants. The Company reserved

20,000,000

shares of common stock for issuance under the Plan. The Plan is intended to provide equity incentives to persons retained by our Company.

Employment Agreements

November 30, 2017,

employment agreements were entered into with

four

key members of management:

•

Under the Employment Agreement with Bahige (Bill) Chaaban, President of the Company, Mr. Chaaban will receive compensation in the form of a base annual salary of

$31,200

and a grant of

8,750,000

shares of restricted stock of the Company, of which

7,400,000

vested immediately and the remaining vesting ratably each month over the next

months.

•

Under the Employment Agreement with Joseph Byrne, Chief Executive Officer of the Company, Mr. Byrne will receive compensation in the form of a base annual salary of

$31,200

and a grant of

1,250,000

shares of restricted stock of the Company, of which

325,000

vested immediately and the remaining vesting ratably each month over the next

months.

•

$31,200

and a grant of

4,500,000

shares of restricted stock of the Company, of which

4,140,000

vested immediately and the remaining vesting ratably each month over the next

months.

•

Under the Employment Agreement with Brian Payne, Vice President of the Company, Mr. Payne will receive compensation in the form of a base annual salary of

$31,200

and a grant of

750,000

shares of restricted stock of the Company, of which

300,000

vested immediately and the remaining vesting ratably each month over the next

months.

Equity Compensation Grants

November 30, 2017,

the Company granted a

one

-time equity award (“Equity Award”) of

20,000

restricted shares of the Company’s common stock pursuant to a Restricted Stock Agreement, to each of the following executives and directors of the Company: Bahige “Bill” Chaaban, Chairman of the Board and President of the Company; Joseph Byrne, Chief Executive Officer and Director; Richard Boswell, Senior Executive Vice President, Chief Financial Officer and Director; Brian Payne, Vice President and Director; Donald Strilchuck, Director; Harold Aubrey de Lavenu, Director; Alex Tarrabain, Director; and Ameen Ferris, Director. The Equity Awards vested immediately.

In addition, as part of this

one

-time equity award, Donald Strilchuck, Director, received an additional

1,000,000

restricted shares of the Company's common stock for security consulting services, of which

550,000

vested immediately and the remaining vesting ratably each month over the next

months. Other individuals received a total of

1,870,000

restricted shares of the Company's common stock for consulting services performed, of which

1,330,000

vested immediately and the remaining vesting ratably each month over the next

months. The expense related to the restricted stock awarded to non-employees for services rendered was recognized on the grant date.

June 7, 2018,

the Company elected Dr. Usamakh Saadikh to serve as a director of the Company. As compensation for his role as a Director, the company granted a

one

-time equity award of

20,000

shares of the Company’s common stock. This award vested immediately.

June 19, 2018,

the Company entered into an agreement with a law firm for the payment of its services under which the Company issued

125,000

shares of its common stock. This award vested immediately. The expense related to the restricted stock awarded to non-employees for services rendered was recognized on the grant date.

Restricted Stock Awards

The grant-date fair value of the restricted shares noted in the employment agreements and equity compensation grants sections above was

$11,423,500.

The grant-date fair value is calculated utilizing an enterprise valuation model as of the date the awards are granted. During

2017,

14,317,500

of these shares vested, with the remaining restricted stock units of

3,962,500

shares vesting pro-rata over the requisite service period, which is generally

three

years from the grant-date. In addition to the

145,000

shares that were granted and immediately vested during the

six

-months ended

June 30, 2018,

an additional

675,000

shares vested. Non-vested restricted stock awards participate in dividends and recipients are entitled to vote these restricted shares during the vesting period.

Compensation expense recognized in connection with the restricted stock awards was

$179,800

and

$347,200

for the

three

and

six

-months ended

June 30, 2018.

Legal expense, included within general and administrative, recognized in connection with the restricted stock awards was

$77,500

for the

three

and

six

-months ended

June 30, 2018.

Restricted stock award activity for the

six

-months ended

June 30, 2018

is as follows:

	Number of Shares			Weighted- Average Grant Date Fair Value per Share		Weighted- Average Remaining Contractual Term (Years)
Non-vested at December 31, 2017		3,962,500		$	0.62		2.92
Granted		145,000		$	0.62
Vested		(820,000	)	$	0.62
Forfeited		-			-
Non-vested at June 30, 2018		3,287,500		$	0.62		2.50

The fair value of the restricted stock grants was based on the valuation of a

third

-party specialist. Unrecognized compensation expense related to restricted stock amounted to approximately

$1,633,700

as of

June 30, 2018.

This expense will be recognized over the vesting period of the respective awards.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 15 - Net Loss Per Share

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

– NET LOSS PER SHARE

June 30, 2018

and

2017.

Common stock equivalents that were excluded for the

three

and

six

-months ended

June 30, 2018

and

2017

are as follows:

	Three-months Ended June 30,				Six-months Ended June 30,
	2018		2017		2018		2017
Convertible debt		4,426,111		3,499,709		4,089,891		2,626,046

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 16 - Contingency	6 Months Ended
Note 16 - Contingency	Jun. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 1 6 – CONTINGENCY In connection with the distribution by Creative of CEN’s common stock on February 29, 2016 and the Form 10 registration statement filed by CEN to register its shares of common stock under the Exchange Act, CEN received comments by the Staff of the Securities and Exchange Commission, including a letter dated May 4, 2016 in which the Staff noted that they “…continue to question the absence of Securities Act registration of the spin-off distribution”. In the event that the distribution of shares of CEN’s common stock was a distribution that required registration under the Securities Act, then the Company could be subject to enforcement action by the SEC that claims a violation of Section 5 of the Securities Act and could be subject to a private right of action for rescission or damages. Based on management’s estimate, any potential liability related to this matter would not be material.

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 17 - Fair Value Disclosures

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Fair Value Disclosures [Text Block]

NOTE

– FAIR VALUE DISCLOSURES

The fair value of the Company’s financial instruments are as follows:

			Fair Value Measured at Reporting Date Using
	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At June 30, 2018:
Cash and cash equivalents	$	22,004	$	-	$	22,004	$	-	$	22,004
Other receivables	$	465,120	$	-	$	-	$	465,120	$	465,120
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC – related party	$	775,328	$	-	$	-	$	775,328	$	775,328
Loans payable	$	10,117,369	$	-	$	-	$	10,117,369	$	10,117,369
Loans payable – related parties	$	1,362,090	$	-	$	-	$	-	$	-
Convertible notes payable	$	4,316,324	$	-	$	-	$	4,585,314	$	4,585,314
Convertible notes payable – related parties	$	2,710,313	$	-	$	-	$	-	$	-

	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At December 31, 2017:
Cash and cash equivalents	$	84,978	$	-	$	84,978	$	-	$	84,978
Other receivables	$	222,562	$	-	$	-	$	222,562	$	222,562
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC – related party	$	775,328	$	-	$	-	$	775,328	$	775,328
Loans payable	$	9,981,883	$	-	$	-	$	9,981,883	$	9,981,883
Loans payable – related parties	$	1,138,923	$	-	$	-	$	-	$	-
Convertible notes payable	$	3,670,172	$	-	$	-	$	3,831,760	$	3,831,760
Convertible notes payable – related parties	$	2,710,313	$	-	$	-	$	-	$	-

The fair values of other receivables, note receivable - related party, and advances to CEN Biotech Ukraine, LLC approximates carrying value due to the terms of the instruments.

The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates.

The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates.

It is

not

practicable to estimate the fair value of loans payable – related parties and convertible notes payable – related parties due to their related party nature.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 18 - Restatement

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Accounting Changes and Error Corrections [Text Block]

NOTE

– RESTATEMENT

As a result of the restatement of the previously issued

2016

consolidated financial statements, as further described in the Company’s annual report on Form

-K for the year ended

December 31, 2017,

the

January 1, 2017

accumulated deficit was increased by

$654,453.

Furthermore, as a result of the audit for the year ended

December 31, 2017,

the net loss reported for

three

and

six

-months ended

June 30, 2017

has been increased (decreased) by

$82,878

and (

$105,754

), respectively, and accumulated deficit increased by

$548,700

to reflect the net correction of the errors identified in previously reported

2017

and

2016

results, primarily related to the recognition of a liability for a commitment of

$5,000,000

worth of common stock to be issued in the future as consideration in the acquisition of the patent intangible described in Note

and related to the

2017

deferral on the recognition of rental expense related to a lease agreement. The recognition of the

$5,000,000

liability in the restated

2016

results created a corresponding increase in the associated cost basis of the patent. The increase in the value recognized for the patent intangible in

2016

caused an increase in amortization expense to be taken in each subsequent period. The deferral of the rental expense as of

January 1, 2017

in the restated results for the

three

and

six

-month period ended

June 30, 2017

resulted in a decrease in the rental expense taken in the

first

six

months of

2017.

In addition, as a result of the restatement of the previously issued

2016

consolidated financial statements, as further described in the Company’s annual report on Form

-K for the year ended

December 31, 2017,

the

January 1, 2017

balance of common stock was reduced by

$3.

It was also determined that the common stock was

-par and the associated amounts recorded within common stock was reclassified to additional paid-in capital.

In addition, certain reclassifications were noted related to interest expense. These had

net impact on consolidated results.

The effect on the Company's previously issued

three

and

six

-month period ended

June 30, 2017

consolidated financial statements is summarized as follows:

Consolidated Balance Sheet as of

June 30

2017

	Previously Reported			Increase (Decrease)			As Restated

Deferred lease expense	$	-		$	244,362		$	244,362
Intangible assets, net		2,246,052			4,196,938			6,442,990
Patent acquisition liability		-			5,000,000			5,000,000
Accrued expenses		287,650			(3	)		287,649
Common stock		85			(85	)		-
Additional paid-in capital		10,000			(9,918	)		82
Accumulated deficit		(15,758,015	)		(548,700	)		(16,316,810	)

Consolidated Statement of Operations for the

three

-months ended

June 30, 2017

	Previously Reported		Increase (Decrease)			As Restated

Consulting fees	$	212,326	$	(104,726	)	$	107,600
Consulting fees and payroll – related parties		-		83,727			83,727
General and administrative		310,283		103,877			414,160
Interest expense		62,825		441,745			504,570
Interest expense – related parties		525,030		(441,745	)		83,285

Consolidated Statement of Operations

for the

six

-months ended

June 30

2017

	Previously Reported		Increase (Decrease)			As Restated

Consulting fees	$	302,327	$	(104,727	)	$	197,600
Consulting fees and payroll – related parties		-		83,727			83,727
General and administrative		873,645		(84,754	)		788,891
Interest expense		1,033,381		(38,594	)		994,787
Interest expense – related parties		124,830		38,594			163,424

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 19 - Subsequent Event	6 Months Ended
Note 19 - Subsequent Event	Jun. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 1 9 – SUBSEQUENT EVENT On July 31, 2018, the Company entered into a Share Purchase Agreement with AstralENERGY Solar Manufacturing Corporation, LTD. (“AstralENERGY”) to acquire 70% of the outstanding common stock of AstralENERGY. The Company will issue an aggregate 2,500,000 shares of common stock of the Company as consideration for the acquisition. AstralENERGY is a manufacturer of architecturally designed solar panels for residential and commercial solar production and has also developed integrated multi-function LED street lighting systems. Consummation of the acquisition is subject to the completion of certain conditions specified in the agreement.

XML 37 R26.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Jun. 30, 2018
Accounting Policies [Abstract]
Earnings Per Share, Policy [Policy Text Block]	Loss per Share Net loss per common share is computed pursuant to ASC 260 - 10 - 45. Basic loss per share is computed based on the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the diluted weighted average common shares outstanding, which includes the effect of potentially dilutive securities. During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of net loss per share. Diluted earnings per share is similarly computed except that the denominator includes the effect, using the treasury stock method, of unvested restricted stock and convertible notes, if including such potential shares of common stock is dilutive. For the three -months ended June 30, 2018 and 2017, and for the six -months ended June 30, 2018 and 2017, the common stock equivalents of the convertible note agreements were not included in diluted earnings per share computations because their effect was antidilutive.

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 4 - Property, Plant and Improvements, Net (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Property, Plant and Equipment [Table Text Block]

	June 30, 2018			December 31, 2017

Improvements in process	$	1,436,278		$	1,430,839
Furniture and equipment		17,668			17,668
Accumulated depreciation		(8,130	)		(3,092	)

Net property, plant and improvements	$	1,445,816		$	1,445,415

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	June 30, 2018			December 31, 2017

Lighting patent	$	6,797,000		$	6,797,000
Accumulated amortization		(778,823	)		(566,417	)

Net	$	6,018,177		$	6,230,583

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 7 - Loans Payable (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Short-term Debt [Table Text Block]

	June 3 0 , 2018		December 31, 2017
Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note is secured by the Company's equipment.	$	9,675,000	$	9,675,000

Mortgage payable to ARG & Pals, Inc., for the original amount of CAD $385,000. The mortgage bears interest at 22% per annum, with an extended maturity date of September 21, 2018.		292,369		306,883

Loan payable to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.		50,000		-

Loan payable to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018		100,000		-

Total loans payable (all current)	$	10,117,369	$	9,981,883

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 8 - Loans Payable - Related Parties (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Loans Payable to Related Party [Table Text Block]

	June 30 , 2018		December 31, 2017
Loan payable to the spouse of Bill Chaaban, President of CEN, bears an interest at 10% per annum. This is an unsecured loan with a maturity date of December 31, 2018.	$	235,590	$	237,423

Loan payable to a former director of Creative, former parent company, bears interest at 10% per annum. This is an unsecured loan with a maturity date of December 31, 2018.		601,500		601,500

Loan payable to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan with a maturity date of October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban’s spouse.		300,000		300,000

Loan payable to the spouse of Joseph Byrne, CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.		100,000		-

Loan payable to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.		75,000		-

Loan payable to Joseph Byrne, CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan with an extended maturity date of August 16, 2018.		50,000		-

Total loans payable – related parties		1,362,090		1,138,923

Less current portion		1,062,090		838,923

Loans payable – related parties, less current portion	$	300,000	$	300,000

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 9 - Convertible Notes (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Long-term Debt Instruments [Table Text Block]

	June 30 , 2018		December 31, 2017

Convertible note payable, bearing interest at 7% per annum with conversion rights for 335,833 common shares. This is due on demand.	$	838,919	$	880,567

Convertible notes payable to multiple private investors bearing an interest at 5% annum with conversion rights for 2,150,463 common shares, maturing at various dates between September 2018 and June 2020.		3,460,205		2,789,605

Convertible notes payable in default to four unsecured private investors bearing an interest at 5% annum with conversion rights for 10,750 common shares, which matured in May and June 2018.		17,200		-

Total loans and convertible notes payable		4,316,324		3,670,172

Less current portion		2,388,806		1,461,979

Loans and convertible notes payable, less current portion	$	1,927,518	$	2,208,193

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 10 - Convertible Notes - Related Parties (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Convertible Notes Payable to Related Party [Table Text Block]

	June 30 , 2018		December 31, 2017
Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020.	$	1,388,122	$	1,388,122

Convertible notes due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 656,250 common shares with maturity dates between September 2018 and February 2019.		1,050,000		1,050,000

Convertible note due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares with a maturity date of October 26, 2018.		48,000		48,000

Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020		224,191		224,191

Total loans and convertible notes payable		2,710,313		2,710,313

Less current portion		1,098,000		2,210,313

Loans and convertible notes payable, less current portion	$	1,612,313	$	500,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

Note 11 - Income Taxes (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	2018			2017

Income tax benefit at Canadian statutory rate		26.5	%		26.5	%
Valuation allowance		(26.5	%)		(26.5	%)

Effective income tax rate		0	%		0	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	2018			2017

Deferred tax asset - net operating losses	$	6,700,000		$	5,900,000
Deferred tax asset valuation allowance		(6,700,000	)		(5,900,000	)

Net deferred tax asset	$	-		$	-

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note 14 - Stock Based Compensation (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Nonvested Restricted Stock Shares Activity [Table Text Block]

	Number of Shares			Weighted- Average Grant Date Fair Value per Share		Weighted- Average Remaining Contractual Term (Years)
Non-vested at December 31, 2017		3,962,500		$	0.62		2.92
Granted		145,000		$	0.62
Vested		(820,000	)	$	0.62
Forfeited		-			-
Non-vested at June 30, 2018		3,287,500		$	0.62		2.50

XML 46 R35.htm IDEA: XBRL DOCUMENT

Note 15 - Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three-months Ended June 30,				Six-months Ended June 30,
	2018		2017		2018		2017
Convertible debt		4,426,111		3,499,709		4,089,891		2,626,046

XML 47 R36.htm IDEA: XBRL DOCUMENT

Note 17 - Fair Value Disclosures (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Fair Value, by Balance Sheet Grouping [Table Text Block]

			Fair Value Measured at Reporting Date Using
	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At June 30, 2018:
Cash and cash equivalents	$	22,004	$	-	$	22,004	$	-	$	22,004
Other receivables	$	465,120	$	-	$	-	$	465,120	$	465,120
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC – related party	$	775,328	$	-	$	-	$	775,328	$	775,328
Loans payable	$	10,117,369	$	-	$	-	$	10,117,369	$	10,117,369
Loans payable – related parties	$	1,362,090	$	-	$	-	$	-	$	-
Convertible notes payable	$	4,316,324	$	-	$	-	$	4,585,314	$	4,585,314
Convertible notes payable – related parties	$	2,710,313	$	-	$	-	$	-	$	-

	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At December 31, 2017:
Cash and cash equivalents	$	84,978	$	-	$	84,978	$	-	$	84,978
Other receivables	$	222,562	$	-	$	-	$	222,562	$	222,562
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC – related party	$	775,328	$	-	$	-	$	775,328	$	775,328
Loans payable	$	9,981,883	$	-	$	-	$	9,981,883	$	9,981,883
Loans payable – related parties	$	1,138,923	$	-	$	-	$	-	$	-
Convertible notes payable	$	3,670,172	$	-	$	-	$	3,831,760	$	3,831,760
Convertible notes payable – related parties	$	2,710,313	$	-	$	-	$	-	$	-

XML 48 R37.htm IDEA: XBRL DOCUMENT

Note 18 - Restatement (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

	Previously Reported			Increase (Decrease)			As Restated

Deferred lease expense	$	-		$	244,362		$	244,362
Intangible assets, net		2,246,052			4,196,938			6,442,990
Patent acquisition liability		-			5,000,000			5,000,000
Accrued expenses		287,650			(3	)		287,649
Common stock		85			(85	)		-
Additional paid-in capital		10,000			(9,918	)		82
Accumulated deficit		(15,758,015	)		(548,700	)		(16,316,810	)

	Previously Reported		Increase (Decrease)			As Restated

Consulting fees	$	212,326	$	(104,726	)	$	107,600
Consulting fees and payroll – related parties		-		83,727			83,727
General and administrative		310,283		103,877			414,160
Interest expense		62,825		441,745			504,570
Interest expense – related parties		525,030		(441,745	)		83,285

	Previously Reported		Increase (Decrease)			As Restated

Consulting fees	$	302,327	$	(104,727	)	$	197,600
Consulting fees and payroll – related parties		-		83,727			83,727
General and administrative		873,645		(84,754	)		788,891
Interest expense		1,033,381		(38,594	)		994,787
Interest expense – related parties		124,830		38,594			163,424

XML 49 R38.htm IDEA: XBRL DOCUMENT

Note 2 - Going Concern Uncertainty / Management Plans (Details Textual) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017
Retained Earnings (Accumulated Deficit), Ending Balance	$ (31,105,003)	$ (28,124,692)	$ (16,316,810)

XML 50 R39.htm IDEA: XBRL DOCUMENT

Note 4 - Property, Plant and Improvements, Net (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Depreciation, Total	$ 4,596	$ 441	$ 5,038	$ 883
Leasehold Improvements Subject to Amortization, Remaining Balance	$ 166,163		$ 166,163

XML 51 R40.htm IDEA: XBRL DOCUMENT

Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Accumulated depreciation	$ (8,130)	$ (3,092)
Net property, plant and improvements	1,445,816	1,445,415
Improvements in Process [Member]
Improvements in process	1,436,278	1,430,839
Furniture and Equipment [Member]
Improvements in process	$ 17,668	$ 17,668

XML 52 R41.htm IDEA: XBRL DOCUMENT

Note 5 - Advances to CEN Biotech Ukraine (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
CEN Biotech Ukraine [Member]
Payments to Fund Long-term Loans to Related Parties	$ 775,328	$ 775,328

XML 53 R42.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets (Details Textual) - USD ($)		3 Months Ended	6 Months Ended		7 Months Ended	12 Months Ended
Note 6 - Intangible Assets (Details Textual) - USD ($)	Sep. 12, 2016	Mar. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Sep. 30, 2018	Dec. 31, 2016
Development of Acquired Technology, Annual Compensation for Specialist	$ 200,000
Noncash or Part Noncash Acquisition, Noncash Consideration, Liability Incurred		$ 4,380,000	$ 4,380,000			$ 5,000,000
Adjustments to Additional Paid in Capital, Patent Acquisition Liability Modification		$ 4,380,000	$ 4,380,000
Finite-Lived Intangible Asset, Useful Life			16 years
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months			$ 424,812
Finite-Lived Intangible Assets, Amortization Expense, after Year Fourteen			$ 283,216
Tesla Digital [Member] \| Scenario, Forecast [Member]
Stock Issued During Period, Shares, Purchase of Assets					1,000,000
Patented Technology [Member]
Stock Issued During Period, Value, Purchase of Assets	5,000,000
Noncash or Part Noncash Acquisition, Noncash Consideration, Carrying Value of Properties to be Transferred	2,161,467
Noncash or Part Noncash Acquisition, Noncash Consideration, Original Cost of Property Transferred	$ 202,666

XML 54 R43.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets - Intangible Assets (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Lighting patent	$ 6,797,000	$ 6,797,000
Accumulated amortization	(778,823)	(566,417)
Net	$ 6,018,177	$ 6,230,583

XML 55 R44.htm IDEA: XBRL DOCUMENT

Note 7 - Loans Payable (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
Note 7 - Loans Payable (Details Textual) - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018
Debt Instrument, Debt Default, Amount	$ 9,675,000		$ 9,675,000
Equipment Pledged as Collateral	$ 11,000		11,000
Stock Issued During Period, Value, New Issues			$ 59,768
Individual Lenders [Member]
Stock Issued During Period, Shares, New Issues	26,000	0	42,400
Stock Issued During Period, Value, New Issues	$ 16,120		$ 26,288

XML 56 R45.htm IDEA: XBRL DOCUMENT

Note 7 - Loans Payable - Loans Payable (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Loans payable	$ 10,117,369	$ 9,981,883
Short-term Loan Payable to Global Holdings International, LLC [Member]
Loans payable	9,675,000	9,675,000
Short-term Mortgage Payable to ARG & Pals, Inc. [Member]
Loans payable	292,369	306,883
Short-term Loan Payable to an Individual [Member]
Loans payable	50,000
Second Short-term Loan Payable to an Individual [Member]
Loans payable	$ 100,000

XML 57 R46.htm IDEA: XBRL DOCUMENT

Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals) - CAD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Short-term Loan Payable to Global Holdings International, LLC [Member]
Interest Rate	15.00%	15.00%
Maturity Date	Jun. 30, 2016	Jun. 30, 2016
Short-term Mortgage Payable to ARG & Pals, Inc. [Member]
Interest Rate	22.00%	22.00%
Maturity Date	Sep. 21, 2018	Sep. 21, 2018
Original Amount	$ 385,000	$ 385,000
Short-term Loan Payable to an Individual [Member]
Maturity Date	Aug. 16, 2018
Share Interest (in shares)	2,000
Second Short-term Loan Payable to an Individual [Member]
Maturity Date	Aug. 16, 2018
Share Interest (in shares)	4,000

XML 58 R47.htm IDEA: XBRL DOCUMENT

Note 8 - Loans Payable - Related Parties (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Interest Expense, Related Party	$ 105,292	$ 83,285	$ 209,578	$ 163,424
Stock Issued During Period, Value, New Issues			$ 59,768
Related Parties Lenders [Member]
Stock Issued During Period, Shares, New Issues	27,000	0	54,000	0
Stock Issued During Period, Value, New Issues	$ 16,740		$ 33,480
Loans Payable to Related Party [Member]
Interest Payable, Related Party	303,541		303,541		$ 248,100
Interest Expense, Related Party	$ 43,367	$ 20,992	$ 86,409	$ 41,677

XML 59 R48.htm IDEA: XBRL DOCUMENT

Note 8 - Loans Payable - Related Parties - Loans Payable to Related Parties (Details) - Loans Payable to Related Party [Member] - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Long-term Debt	$ 1,362,090	$ 1,138,923
Less current portion	1,062,090	838,923
Loans payable – related parties, less current portion	300,000	300,000
Mr. Chaaban's Spouse [Member]
Long-term Debt	235,590	237,423
Jeff Thomas, Former Director of Creative Edge [Member]
Long-term Debt	601,500	601,500
R&D Labs Canada, Inc [Member]
Long-term Debt	300,000	300,000
Spouse of Joseph Byrne, CEO of CEN Biotech [Member]
Long-term Debt	100,000
Director, Alex Tarrabain [Member]
Long-term Debt	75,000
Joseph Byrne [Member]
Long-term Debt	$ 50,000

XML 60 R49.htm IDEA: XBRL DOCUMENT

Note 8 - Loans Payable - Related Parties - Loans Payable to Related Parties (Details) (Parentheticals) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Mr. Chaaban's Spouse [Member] \| Loans Payable to Related Party [Member]
Interest Rate	10.00%	10.00%
Maturity Date	Dec. 31, 2018	Dec. 31, 2018
Jeff Thomas, Former Director of Creative Edge [Member] \| Loans Payable to Related Party [Member]
Interest Rate	10.00%	10.00%
Maturity Date	Dec. 31, 2018	Dec. 31, 2018
R&D Labs Canada, Inc [Member] \| Loans Payable to Related Party [Member]
Interest Rate	8.00%	8.00%
Maturity Date	Oct. 02, 2019	Oct. 02, 2019
Spouse of Joseph Byrne, CEO of CEN Biotech [Member]
Maturity Date	Aug. 16, 2018
Share Interest (in shares)	4,000
Director, Alex Tarrabain [Member]
Maturity Date	Aug. 16, 2018
Share Interest (in shares)	3,000
Joseph Byrne [Member]
Maturity Date	Aug. 16, 2018
Share Interest (in shares)	2,000

XML 61 R50.htm IDEA: XBRL DOCUMENT

Note 9 - Convertible Notes (Details Textual)	6 Months Ended
Note 9 - Convertible Notes (Details Textual)	Jun. 30, 2018
Convertible Debt [Member]
Debt Instrument, Convertible, Number of Equity Instruments	2,497,046

XML 62 R51.htm IDEA: XBRL DOCUMENT

Note 9 - Convertible Notes - Convertible Notes (Details) - Convertible Debt [Member] - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Long-term Debt	$ 4,316,324	$ 3,670,172
Less current portion	2,388,806	1,461,979
Loans and convertible notes payable, less current portion	1,927,518	2,208,193
Convertible Payable 1 [Member]
Long-term Debt	838,919	880,567
Convertible Payable 2 [Member]
Long-term Debt	3,460,205	2,789,605
Convertible Payable 3 [Member]
Long-term Debt	$ 17,200

XML 63 R52.htm IDEA: XBRL DOCUMENT

Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Convertible Debt [Member]
Conversion Rights	2,497,046
Convertible Payable 1 [Member] \| Convertible Debt [Member]
Interest Rate	7.00%	7.00%
Conversion Rights	335,833	335,833
Convertible Payable 2 [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	2,150,463	2,150,463
Maturing Dates Range	Between September 2018 and June 2020	Between September 2018 and June 2020
Convertible Payable 3 [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	10,750	10,750
Maturing Dates Range	May and June 2018	May and June 2018

XML 64 R53.htm IDEA: XBRL DOCUMENT

Note 10 - Convertible Notes - Related Parties (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Interest Expense, Related Party	$ 105,292	$ 83,285	$ 209,578	$ 163,424
Convertible Debt Payable to Related Party [Member]
Interest Payable, Related Party	465,466		465,466		$ 344,801
Interest Expense, Related Party	$ 61,925	$ 61,026	$ 123,169	$ 121,747
Debt Instrument, Convertible, Number of Equity Instruments			1,693,946

XML 65 R54.htm IDEA: XBRL DOCUMENT

Note 10 - Convertible Notes - Related Parties - Convertible Notes Payable to Related Parties (Details) - Convertible Debt Payable to Related Party [Member] - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Long-term Debt	$ 2,710,313	$ 2,710,313
Less current portion	1,098,000	2,210,313
Loans and convertible notes payable, less current portion	1,612,313	500,000
Bill Chaaban, President of Cen Biotech [Member]
Long-term Debt	1,388,122	1,388,122
Director, Harold Aubrey de Lavenu [Member]
Long-term Debt	1,050,000	1,050,000
Director, Alex Tarrabain [Member]
Long-term Debt	48,000	48,000
Joseph Byrne [Member]
Long-term Debt	$ 224,191	$ 224,191

XML 66 R55.htm IDEA: XBRL DOCUMENT

Note 10 - Convertible Notes - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Director, Alex Tarrabain [Member]
Maturing Dates	Aug. 16, 2018
Joseph Byrne [Member]
Maturing Dates	Aug. 16, 2018
Convertible Debt Payable to Related Party [Member]
Conversion Rights	1,693,946
Convertible Debt Payable to Related Party [Member] \| Bill Chaaban, President of Cen Biotech [Member]
Interest Rate	12.00%	12.00%
Conversion Rights	867,576	867,576
Maturing Dates	Aug. 17, 2020	Aug. 17, 2020
Convertible Debt Payable to Related Party [Member] \| Director, Harold Aubrey de Lavenu [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	656,250	656,250
Maturing Dates	Between September 2018 and Feb 2019	Between September 2018 and Feb 2019
Convertible Debt Payable to Related Party [Member] \| Director, Alex Tarrabain [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	30,000	30,000
Maturing Dates	Oct. 26, 2018	Oct. 26, 2018
Convertible Debt Payable to Related Party [Member] \| Joseph Byrne [Member]
Interest Rate	12.00%	12.00%
Conversion Rights	140,120	140,120
Maturing Dates	Aug. 17, 2020	Aug. 17, 2020

XML 67 R56.htm IDEA: XBRL DOCUMENT

Note 11 - Income Taxes (Details Textual)	Jun. 30, 2018 USD ($)
Operating Loss Carryforwards, Total	$ 25,300,000

XML 68 R57.htm IDEA: XBRL DOCUMENT

Note 11 - Income Taxes - Reconciliation of Effective Tax Rate (Details)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Income tax benefit at Canadian statutory rate	26.50%	26.50%
Valuation allowance	(26.50%)	(26.50%)
Effective income tax rate	0.00%	0.00%

XML 69 R58.htm IDEA: XBRL DOCUMENT

Note 11 - Income Taxes - Deferred Tax Assets (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Deferred tax asset - net operating losses	$ 6,700,000	$ 5,900,000
Deferred tax asset valuation allowance	(6,700,000)	(5,900,000)
Net deferred tax asset

XML 70 R59.htm IDEA: XBRL DOCUMENT

Note 12 - Shareholders' Deficit (Details Textual) - $ / shares $ / shares in Thousands	Jun. 30, 2018	Dec. 31, 2017
Common Stock, No Par Value	$ 0	$ 0

XML 71 R60.htm IDEA: XBRL DOCUMENT

Note 13 - Related Party Transactions (Details Textual)		1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
Note 13 - Related Party Transactions (Details Textual)	Sep. 01, 2013 CAD ($)	Jan. 31, 2017 CAD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2018	Dec. 03, 2017	Dec. 02, 2017	Jul. 12, 2017	Jan. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
General and Administrative Expense [Member]
Operating Leases, Rent Expense, Total			$ 23,000	$ 23,000	$ 46,000	$ 46,000
Lease Arrangement, 20 North Rear Road [Member]
Operating Lease Annual Rent	$ 339,000
Accrued Rent													$ 552,934
Operating Lease, Monthly Rent		$ 4,000
Lessee, Operating Lease, Term of Contract												5 years
Long-term Convertible Notes Payable to Multiple Private Investors [Member]
Debt Instrument, Interest Rate, Stated Percentage											5.00%
Convertible Debt Issued to Lessor's Creditor [Member]
Convertible Debt, Total												$ 824,446
CEN Biotech Ukraine [Member] \| Scenario, Forecast [Member]
Business Acquisition, Percentage of Voting Interests Acquired								51.00%
CEN Biotech Ukraine [Member]
Due from Related Parties, Total			775,328		775,328		$ 775,328
Percentage of Related Party's Equity Interest Owned by Director									25.50%	51.00%
CEN Biotech Ukraine [Member] \| Equipment Sold to Related Party in Exchange for Note Receivable [Member]
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings							255,141
Notes Receivable, Related Parties							44,859
Board Members and Officers [Member] \| Consulting Fees [Member]
Related Party Transaction, Amounts of Transaction			45,839	$ 0	77,039	$ 83,727
Due to Related Parties, Total			$ 62,400		$ 62,400		11,986
R&D Labs Canada, Inc [Member] \| Purchased Equipment in Exchange for Note Payable [Member]
Notes Payable, Related Parties							$ 300,000

XML 72 R61.htm IDEA: XBRL DOCUMENT

Note 14 - Stock Based Compensation (Details Textual) - USD ($)				3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 19, 2018	Jun. 07, 2018	Nov. 30, 2017	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017	Nov. 29, 2017
Stock Issued During Period, Shares, Issued for Services	125,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					145,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period					820,000	14,317,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant DateFair Value					$ 11,423,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance				3,287,500	3,287,500	3,962,500
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						3 years
Allocated Share-based Compensation Expense, Total				$ 179,800	$ 347,200
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options				1,633,700	1,633,700
Restricted Stock [Member] \| General and Administrative Expense [Member]
Legal Fees				$ 77,500	$ 77,500
Restricted Shares Issued for Consulting Services Perfomed [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			1,870,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period			1,330,000
Vesting Pro-rate Over the Requisite Service Period [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance						3,962,500
Vesting Immediately Upon Grant [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period					145,000
Vesting in Periods Subsequent to Grant [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period					675,000
President [Member]
Employment Agreement, Base Annual Salary			$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock			8,750,000
President [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			20,000
President [Member] \| Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock			7,400,000
Chief Executive Officer [Member]
Employment Agreement, Base Annual Salary			$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock			1,250,000
Chief Executive Officer [Member] \| Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock			325,000
Senior Executive Vice President and Chief Financial Officer [Member]
Employment Agreement, Base Annual Salary			$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock			4,500,000
Senior Executive Vice President and Chief Financial Officer [Member] \| Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock			4,140,000
Vice President [Member]
Employment Agreement, Base Annual Salary			$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock			750,000
Vice President [Member] \| Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock			300,000
Director,Donald Strilchuck [Member] \| Restricted Shares Issued for Security Consulting Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period			550,000
Director [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross		20,000
2017 Equity Compensation Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance							20,000,000

XML 73 R62.htm IDEA: XBRL DOCUMENT

Note 14 - Stock Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Non-vested, number of share (in shares)	3,962,500
Non-vested, weithged average grant date fair value (in dollars per share)	$ 0.62
Non-vested, weighted average remaining contractual term (Year)	2 years 182 days	2 years 335 days
Granted, number of share (in shares)	145,000
Granted, weithged average grant date fair value (in dollars per share)	$ 0.62
Granted, weighted average remaining contractual term (Year)
Vested, number of share (in shares)	(820,000)	(14,317,500)
Vested, weithged average grant date fair value (in dollars per share)	$ 0.62
Forfeited, number of share (in shares)
Forfeited, weithged average grant date fair value (in dollars per share)
Non-vested, number of share (in shares)	3,287,500	3,962,500
Non-vested, weithged average grant date fair value (in dollars per share)	$ 0.62	$ 0.62

XML 74 R63.htm IDEA: XBRL DOCUMENT

Note 15 - Net Loss Per Share - Antidilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	4,426,111	3,499,709	4,089,891	2,626,046

XML 75 R64.htm IDEA: XBRL DOCUMENT

Note 17 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Reported Value Measurement [Member]
Cash and cash equivalents	$ 22,004	$ 84,978
Other receivables	465,120	222,562
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine, LLC – related party	775,328	775,328
Loans payable	10,117,369	9,981,883
Loans payable – related parties	1,362,090	1,138,923
Convertible notes payable	4,316,324	3,670,172
Convertible notes payable – related parties	2,710,313	2,710,313
Estimate of Fair Value Measurement [Member]
Cash and cash equivalents	22,004	84,978
Other receivables	465,120	222,562
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine, LLC – related party	775,328	775,328
Loans payable	10,117,369	9,981,883
Loans payable – related parties
Convertible notes payable	4,585,314	3,831,760
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents
Other receivables
Note receivable - related party
Advances to CEN Biotech Ukraine, LLC – related party
Loans payable
Loans payable – related parties
Convertible notes payable
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents	22,004	84,978
Other receivables
Note receivable - related party
Advances to CEN Biotech Ukraine, LLC – related party
Loans payable
Loans payable – related parties
Convertible notes payable
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] \| Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents
Other receivables	465,120	222,562
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine, LLC – related party	775,328	775,328
Loans payable	10,117,369	9,981,883
Loans payable – related parties
Convertible notes payable	4,585,314	3,831,760
Convertible notes payable – related parties

XML 76 R65.htm IDEA: XBRL DOCUMENT

Note 18 - Restatement (Details Textual) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
Note 18 - Restatement (Details Textual) - USD ($)	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2017
Retained Earnings (Accumulated Deficit), Ending Balance	$ 31,105,003		$ 16,316,810	$ 31,105,003	$ 16,316,810		$ 28,124,692
Net Income (Loss) Attributable to Parent, Total	(1,659,541)		(1,224,295)	(2,980,311)	(2,272,572)
Retained Earnings (Accumulated Deficit), Ending Balance	(31,105,003)		(16,316,810)	(31,105,003)	(16,316,810)		(28,124,692)
Noncash or Part Noncash Acquisition, Noncash Consideration, Liability Incurred		$ 4,380,000		4,380,000		$ 5,000,000
Common Stock, Value, Issued, Ending Balance
Error Correction Related to Equity Transaction for Shares Issued for Services Not Provided [Member]
Common Stock, Value, Issued, Ending Balance						(3)
Restatement Adjustment [Member]
Retained Earnings (Accumulated Deficit), Ending Balance			548,700		548,700	654,453
Net Income (Loss) Attributable to Parent, Total			82,878		(105,754)
Retained Earnings (Accumulated Deficit), Ending Balance			(548,700)		(548,700)	$ (654,453)
Common Stock, Value, Issued, Ending Balance			$ (85)		$ (85)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 77 R66.htm IDEA: XBRL DOCUMENT

Note 18 - Restatement - Effect on Previously Issued Consolidated Financial Statements (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Deferred lease expense	$ 190,058	$ 244,362	$ 190,058	$ 244,362	$ 217,210
Intangible assets, net	6,018,177	6,442,990	6,018,177	6,442,990	6,230,583
Patent acquisition liability	620,000	5,000,000	620,000	5,000,000	5,000,000
Accrued expenses	339,977	287,649	339,977	287,649	295,874
Common stock
Additional paid-in capital	13,974,509	82	13,974,509	82	9,110,041
Accumulated deficit	(31,105,003)	(16,316,810)	(31,105,003)	(16,316,810)	$ (28,124,692)
Consulting fees	48,500	107,600	60,485	197,600
Consulting fees and payroll – related parties	45,839	83,727	77,039	83,727
General and administrative	694,595	414,160	1,136,434	788,891
Interest expense	608,670	504,570	1,203,173	994,787
Interest expense – related parties	$ 105,292	83,285	$ 209,578	163,424
Previously Reported [Member]
Deferred lease expense
Intangible assets, net		2,246,052		2,246,052
Patent acquisition liability
Accrued expenses		287,650		287,650
Common stock		85		85
Additional paid-in capital		10,000		10,000
Accumulated deficit		(15,758,015)		(15,758,015)
Consulting fees		212,326		302,327
Consulting fees and payroll – related parties
General and administrative		310,283		873,645
Interest expense		62,825		1,033,381
Interest expense – related parties		525,030		124,830
Restatement Adjustment [Member]
Deferred lease expense		244,362		244,362
Intangible assets, net		4,196,938		4,196,938
Patent acquisition liability		5,000,000		5,000,000
Accrued expenses		(3)		(3)
Common stock		(85)		(85)
Additional paid-in capital		(9,918)		(9,918)
Accumulated deficit		(548,700)		(548,700)		$ (654,453)
Consulting fees		(104,726)		(104,727)
Consulting fees and payroll – related parties		83,727		83,727
General and administrative		103,877		(84,754)
Interest expense		441,745		(38,594)
Interest expense – related parties		$ (441,745)		$ 38,594

XML 78 R67.htm IDEA: XBRL DOCUMENT

Note 19 - Subsequent Event (Details Textual) - Subsequent Event [Member] - AstralENERGY [Member]	Jul. 31, 2018 shares
Business Acquisition, Percentage of Voting Interests Acquired	70.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,500,000

EXCEL 79 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
UUVQ Y[5G?LP 7JP,V.60H(^JXU H)3UWW;97H\(3=/GT >'?0M=PQM^WU[ MBY(\ #G1@_F-1KU&A=F$(-/VFF%KS>F6V\"@]F!@V0/@2=#H*U#TJ;_F5DGZ M@O1$_EE[OW*QGCZ&:ST9N46EXJ4@S(, I#L0 ,*#_(,&%6D47QK%#R!=A,$* MIEM,%,%(0@#=>$&ZBK(EF5:XFO!/[J6"=8>-61Q%:]HA>O#35&XP8NX7:0=L M4=L<)#9S@8X[.8H-^>HR,F*0SPBLG94M0LR$ZWXJN@#.^98?>D4IY MPH B8*H4# 66AHY@(0Y<0(++#AP@5N"XP1#DJXW_.7BSZP"C#X1FWH@PME], M.^:8$TC\@FX3$).R9+PU&3!W/ D\0,L2-QZ R<)YAZ&J"(!F@:P!::GPIY5( M@PFN<_GF+8&C\6D'=0/>D7Z$1?-!@X3L+G^Y$C',+!&,)"!%QQ6H,8R":/E, M72C6*K,A<9B(+X("XT"CX.H!!?_=FTM;,>2"OW(?90'&6!!M=,@IV!67QA3M M2T') NU.MPO62Q?!NO1B8!HI-EP6 ?6N 29L7Y"!HN<."KW>2+RLF>LQ?_0Y M&%E!%"Z/ R")A;) R0&#J?HQ-7Q: ;7,_1A$-]J1<[)#%K@#(9 W]^*8C&MO MC6J=3-E0]*5,I/SOG5B3TESU:UWQ>%I MF1T.AR-KY/10];@@@/O0J5 ^^#IBV!X.Z=H!,%Q0"#B%H#*LC_:T1 'VC09O M"B(-6@%J80J@*6+F;4!)?/;!B>4@2U%E]9T^Z"X'YH(S.G!&/\HZ DC\$T3W0](]1L*!-0]I,#CVQ^6AA2IORF.XY[L;FT710;K;[-3G% MH BS-?,>X E:^9[8 P8 M&5AHXU17R N)PQ_]188K(G-(46;;_)/N_^R29W563E)E0)>8]]((\0_ ([>2N9<,B(@4@,8]'-E$!4MZ! M1N>V+2CR)*.)DK:MF\SP_T"V!_,5S-JKR-!L6.JF9E-;K.]8?>P$.G-&M3U0 MDGVCJNR#W[I5: @#EYOO;T6.&H2CNGM[>C&Y.SV!^[=W#&.SK1(G6_AE[:4I MX7,392( ]!Y-D^G*\^X],%HP9 UFGQ0SIU>6%"A$^9I0[6HR93=AULFQ"B7: M',SIN>!K=>EJ:/4=@YA!J;A&"0YVT#P%"8E@@BN!<2!+/=Q08AV303S+I!1^ M _@'7=MR@2#5WRKLMR3B3]B%=Y^P*5A5"T^)^J=5!(NQR7$/H)27!=2"6#?S M^B"7Z-,;O7)VUX!:DO\TMW''!#OUJ'#,HJ=0*$0=[CP()J@-$Q:$T%%_MU/F M3X"4S8J]?XY#CN;X=3[GJGIQ7JQ>?G_)V]%$;W7^DX!_9G=@' /V?%QV\< M.C=-_>6:M?<'3%TJBOK,6Z^UT__G-"5,6K9)V-N@: %8D(2V9?=&UA@EH2%% M'1YW9<.1:O;R-'P0NXHOBZN*ZSA)T]B_SU)/N.9:#0E&T8,(*27+0ZUG]$752;30T^V=C( Z]9.'*E$=Q@1[W'B[:.%_ZZ?75I]/; M.PK]X*-9:;!R?<1.I[K9QJAV6I1LF/334'?)9 0CSRF0L19T?WI@$(QZO3+/ M%AR*20=P>\'77KA X*XP$8;=30"UWM0ARO1A::YGFI&@NY7>& M50V4->A:3M>%(88C,+OAJGE^F)PLW%R*WT99K(FS+SIA< Z&;K#3GM,'= R&X)8,';-L!']U-+)&W0$& M^0>V-1Z.I73<.D"C;(0>0%"X-FYB. VB+,Q>4")Z@$C5N"38/RH7TLN%KDK M71.SMW%*%/O77][3/[&[;;"PRP_Y(B)"Y@SMYX[H89ZJ4^+4S5X5LM%G"F.. M!K"4PT'%&&@RAY56)UL+.1&I :G+=IS2=9T;Y1Q_]&),1)QD]S&'?CD8TH\\ MS(P6GDE@NJUG-G#!':YRHYA9:5Y;A8Z^CPK6/Y@9THXIKII6LX4)^[H)]KH& M,VZG(Y,;9&"&X.OR3^."-=NC)NCWH#R[WZ68QXLHCSE@_MIC.__;7FZ"R@ Y MW;-[VE6333D6R $IIQJ^2FX.P#_#7@[ &OXR5F5_X(),'X"UU>^#B+=;&)6H M 1Q77'2=P3:KTG9ZEHV1+MNQP2)LMBNKPA^F.NY9XR;A;]..'Y51W7F?#(1X M_;; K<)3"9141!Y\+]3 (?B=0<=E7ZL_G[Q )EIY.!9E(AZ*9T?%Q6F.ALJ, M6!?ZP'^3^KX\[KBXEG*.2.%W<>^EW\GWJ_#?#G+4)YK7VN/P8@?LF#(Q:BE/ MM#F5.VBN-9;7AAX>31@HWL:-J_QUL76UJ'=R0 6IQR#1 U'FP# 7+8I1+RQ\ MP!XP.E6CX$*OUVKC^#ZBA$<5)0^$T22/,M0&I0GWLQ6-%-N'LQ\GMZ8_7%R>GMS-5(GQR>G8^/;\K)9U MUS!="F2(J((JS@9M@72A51$)=4 %GN:&6%Z-&'J,TCS* 2[1M/0^922&M4-. M!.IZ%7OSF=UI&>'U?/^FEOLAL&>,@/_,[FXG5[/)].[\6B9?ZKF XM0+&7Z1 MR7T))BD" FHQ#6B_H,SJ>]RQO8^(LZ61C/L='9E203FWZ],VPAHR4N95,= M=)LS=6&&5A?;C'K6$)R8JDPSZDNYNV*#WAP-\AB*?)H'BAS7M6R,[Z B=L?H M7H"A,NA(C.D+2H>))"@P82WZ+'V** U!1E_PTA4A21%)P5>AK9:D0K#U,,0R MQA9UN >8V^ ZUK@'B-62# E-U.D#RON#$5A/_?Z N=OPZ@A@&G':ISTL,XMA M?J"HG7WOB3*\YB))C8O0Q-0S.13O3:,$\_-(WLDRM!M1A//2-$Y;RQ^3V; DV ^W)P"/R([EC(]I> L@8-3@.VK[ M]!:[C#NJF9BHPLI9N"X+YG)+3CI MF!K^/DJ>>! [?+0!XNOF,TGF(NV1")E&2=OGM:YEW/50J1QM(/;/'ZJ$MB>X6'+[8GZ?Y M<063)TK\1M6PQ&D:+_@?'^#%?@'N!YAR(;Z)+.LZ.G>&"?J(%+2J,.PZ2'>*9= JY-%!YCA!LM0E.Y5;%&!ZS;&3C,Z8P= 0J\ MHE9,/OLD.CH<..A9SFA8'L\5ILYV(B9L2T+$ M515&@,Q=*[P]DA+ H+ H![8UZ/70Y:NNHMED<:GZI'H*2K5M?FQ'WN+%!DB1 M;HW5"1?7LQF[.;T5[I6R-L66;"+R245V.64=J.,#,#$B8)L(,RI]\C7IC!64 MI,J3HO*"U#_.'Y!O%>.I=O,@PTU<\BI$5FHPE\6 B$EU7$NHE]91MQUIUDG\ M5TM^*" R+\55]]7@ MYFJM P4/$:/8 12# .?U@"3Q\!X-Y/Q0&RPR(/7:J?45<]HF^IG MM.WGT&K9]=-KJK<]O9K^C&K3F,V-1S5AC!/O8AZ]S%F28>6B7$Q?^TBO:!+: M<8 >%NZD]>5/M[&>S,;,7TV4GC17D)M;M4%"D0M\-CF_99\F%Q^!>\]G4V#H MC[>G,P& D&N^R*7?Q&@:B<*3* L66'F2._HY48-]PTMYX5$L:MPQ<(11B >, MMVN'W$"K;"UW,*,8K#60!EJIN]+]ZPA#]NC^IZ!#< MV[<6_<@HOTG/B2V'5 MH77187FY,0.![-T'?K)"QF%@K<88Q,;3V[3R?)B"M^9/4?RKF"-,-\("XG^H MBF,O_%4@(L ,?YQC=(^B4:N?]$-@Z"0_AD+ 1">,Y=CL-&B-JC#2RZ&!!#-) M^S'7@K'?ZF1R*1! RJLX@9?T\L>$E*U*WI^(?.0+FH8M_SKR;T_OLUHP\RUK M/!X!=U^IJ6ZH&TXL(SA!UWT9TH[XU'JJE,?TP$9T#!.D.' W: MXHZZ^F.8[!5IE$H!?U7A:=IR <_Q@/_ MX+[P6:HQJ]\<3[V./-*@&%8>=8*"(0";-#]X4;IO(A"E! 5N"U9.?NO(M (\ MG +ZOLMW["ONYC>) ?8F1#4?45SV )EL?U/T+&Q >.U<':)U>)(?K#5)%(,L MF/G4>*47097UA%Z45^;CXS'I!'=67 ?CL..!->Z-V,#J]QUK#.;*UF,NCUE! M2\55]31TAA&8@=MEAUC!23_ZXWS_E/RND-=\@1!" 9=5CL\&*S7D>."?80).BYS 51W:&C7!).+$68@]T/5PQ%"YXS< M_=8!&4W%.K@>ZW@-']47I=?%11D6BS(4BS+^719E- 0SK(\LT2>Q?L2&F%@[ MMNOHM@&I/:LWLH&Y1I8[QL;C,;PV&K9?&QLKG &%L@=[T+/ZX'.8531FS^.! M46#,XS*=/AKT=/5YJ\#&.-^3[^4GV R[7S-'[1/51ME^W!P[5%>UDU6-Y[]- M[A,*:=<_*E0+P5KBM6?VB_R[979_WF/#6I^IPP[OR "OX5&D>MP9/Z*R_>"= M7^BE+7AK^%[#_^TC<=H?6]*X)+/YBB\R$,+BO/5N_BMUN /..^A MW3D,K9!6/YSA-5AZ.W/A[MQ,W.TP]>):/?CBAX M.Z+@[8B"/[^@>CNBX.V(@G^>(PK:5]6W5(&E4OMS;0OA-U-_;]7S;]7S_Q^K MYU]5)-^*F^O]_/[&[5OA^UOA^UOA^UOA>Y.M4BL,;R79BOIEK6[\%M%W6R[[ M?JE<^U,58V_#1+[QC!B8%)_$N- ^?_%Z)/SY"[7WKT7[QLN?^T%0/- M6?*->"V:6Q1/*N73?(BC;(,4^%),O>5B_UG38M]RL=]RL=]RL7_G7.Q6J;GM M+.9:8B[2WPW6YZ""\R/P4[4/%K]4?K_E3O[>N9-OJ8]?)/7Q+5GQMTU6W/?# MF(AS>!@D)(/ D=GR=?9;;(G[F[G)?J@SE#PN9OEF]*U>O=F1@)<'P1B88_G))]E8M_;,A(;'FX)3R$+4\R89NVWZM;1^" ML1UVJ?F$M4IN0^]-X.6')>'7G3.,#.5[?,)FJNP%-'P=NBGWL?V<9GS3R3^V M5GUXZ<6=/%?#^*9RV>J\-<_?K'5[4OZ.V$1]0^PN_X:8Q2;B3)E2: CWIF;B ML#G?^#5Q,MS1=,*#8=3O26%=6/G-J?XM.2N/RSVC=J%OO=:_XE>88?U-C<:WI:-:X%_SARR OAYJ8L4>L&>,)>W5 M(\@877JQ4Z%84/* ?7GWQ /07H+@OTR_(NL2@U[L+,I F?,:"DJ?SLNYA_T/ MF\UYB%NL%L:Q.*QA,^N+H*#\%*L\MD,8T_+ ,@#P)HOG*T]LJ &73;C=IK:* M)'1*BM*VT'=GB3?/KN@U3]#6>C8E:+?IJPHA_-)0WM@![IDMV*O[V1OIAS>4 M";KB*9XC0JN F>:&5B0[Q+'E2S5+)!=09CZ;9,L.9IXUO"UV&/)Y'OIJF]A8ZM,NZ;F]Y,C' MS55H*3]DV\&X.-(N9MZ56MUDL2NH;M1V\U:H6B.FVJ)N I-O33E M0S>+D9V9P;G3TM2%@M*J9)0T3U4;:;M<^N)T81!>@F'W6CLP.%_('';7)*.4 M.]0@95Y&&B\'V,_Q($ M5GG;# 9EL]Y2-NM^. "B;TU.0Q.9;S%XY!YY I92N*S9/>];I O7^ZUDW[XR M;U;?FV0!WM MU71#BNL?C:U=_%MFE=<3!3#T*U%J&ST.X3,,A3ZK<^:+ 'WYXFT1'F?\GIDT M[BLA;&D%"JW?Z%J]"(CVEJ4AA767B+O.TR8IFXV":@]13"=7-VP0-0QU7,UX M+67'YFFQ.6O47:P]TEMK;O*@X]:)UI#U6FUR*-ZL0=.8"EMM:+1]&U%D2I)M M$?IIG?7:XD5#LJMI#ZR>X6J>9.,G@(Q._P%[IW+.M4M@*/ $L@3XUR "*:V! M@G 8D47^$.$],SS;OZNSFR$HM-*57SEIB ']Y(6%/F]HH^M\\U915WZIQOS0 M,3_\*0ORO:OZ0QVN%K;(H*&-OK,_*>_LRZA,LP LY E]: 8#):$6S&G>HNV0:AOMUAP3ITP:T[-*-Y;8!J(LC'ICC)1P M:%-[B9*<1<43)3[7[&7SIM6V3XMJ.N)2%?O=R-JW\[SVK;436 I@6N)PK04& MM.><#F/>J;-D)!S 02Q$\3<).NL+'QWW-MX2=M) "-NVD_?;$'N?)?!RDI0W M=(I9XAI]$A_O4@A)\EW9VJ+9Q@!'QD6Z=L7Z:YA;>>R2B (,YCZX7)QK52:O M3)":QG--&F\' HL=EAG:6S6KP\>=RSF=HDD[SR12;XM,S29L[[%3?(*Q>PZ" M7@Z&:T3XJ&3.F*1[HL%B5=%>HX (OXHA !;1!/DEFZ3B_:I$J#-,A&H,'S6I M%+691;/0[INHI>XI--!*FV"5VEW5,T.,ZZ?DQS;3,9BS\;N-#]1VLE^SGR:>4?2%RC R?Y*N4Y#3OBA4?#"OA25-X MR.F&#XN)3^U8A@B=3+Y.5_CQ+_H^&$ M/RJ$&4@TGS\.$EF1\R> I*A>*I+A M_SAH\HHN%7_=E0KX!4"C/[0B!:57A^F9S9()> ASD@:-<&RW[,1GNCC/,_6: M^M%0([\O997' ;D#,*;D9(KO,)4_Q2<_2E5'>FN^!9GZ"L/W@B_A1=0AVP84 M_HXF733]HP0-+M$#.(W-%F^^EG%T3.69UX_RLVBW7%@[!<)E2KTVR=:"2PUS MO@9@P*GG8 Q_W*B/E[VJRUPP)/JYH9C)\.*NBT!74PO3-^,L4F#*9YC1Y]S: MO5>F7KFR9,F4 =X-Y^MF"6]+::NO4Z,AWO YPY>VWV_TUWQ_\+?L<[]95 ;8 ML]E^8^41R!,TIY$Z8C^8K[*RW-HJ8F29Z;-1UNP:]U594 M]%Y?B91/^R_WI]]BJ?-R^;U T=[ZPH2WI=C^N+&47N= ,X?5(EK:VXT1CJ;1 M=F3';2ML+SV(=/VDNQ$MM@?R.K%2O?K66I&7%]#6K".PZ-;RO)AZT?Q6(/9X M%92<7N]_3I]FL_+"Y]]ZA.8\D"\UPH[:_56M\\N 1C2D6OA?F/$?<@%+[6F;Y.C3NB9HC\M6XMT0Q+#N9:95, MM5EEO'=)DO[POU!+ P04 " !5?PY-[:&I8R\" !\"0 #0 'AL+W-T M>6QEVP+='%E M>6OGZZN++[M;2LNV*X9W%< &G6V$6KMSCX<]*S\->\ M)G9 ?6&I@Z&&-"ZDF$LYQQXPN0D'M"4LP=>$T8VB=E5!.&6]AY<6R"23"FG3 M0Z,MLDCSZ,.1]VQ[!QY.A50NM\_@OYMA^D%@]*Q RMA>KRV0QC71&I2X,8Z; M[,"?0FBPUWUM%):*]-'2-\!/=8-)LI$J!S6EB? (I3&#PLI1M*SLJ&4=V*#6 MDALCIZ24@C@-XXK!,+09,'9O]][78H^[*Y"?8W])B)%5,9JFZL&<_UKH).^R M>>X=VLNC:%%-MU)_;$TUPOEVZ\"=@H)VSN^**;]A)W7-^@^,EH*#K^6W":,C M$Z8Q&?.@2BKZ:/CL3LD, JC+2A-LUWDNR+U&CH][J:N.%;S\@5J_M=]+D& M(FQ7M-GZS[G+_UGQ^;N_E^P.E4/!SZNK3RW1WG4O0.3%$XL,AN-\Y\[8NS$F M%&U:RC05@]R*YCEX/?;*3O"M?2VPO8-[OC@,O28;\Q3:XS=K&PO=V]R:V)O;VLN>&ULQ9K;;N,V$$!_A?!+MT!3F^(E M%R0!LG%:!"A2HTGWG9;HF(@LI:*YG7](KZMRBI>C99M^WHQ'L=\Z5K5M7 MA:^B+P1\BW49"N HQ&=7NBKW D%F!&1V3$B%(!4!J8X"^9APX*\(4A.0^IB0 M!D$: M(<$](B2$M VL-"/M2M%U*KB)D80,B:DC",/K)R.\!0(_ZA=%<7,O;L. MX <=I1IY8-=T=&>[='#\5VK=PZ1D(P]LFP[S'+ @\+S!I.GN2! M5;.)XI-]B&DT,2;E&LDB&]E-F+Q>>?'DOO4'D9*,Y+",3)IY7+K&+^NR\$W\ M24P]=!!:C$EI1G)X1JK_9DD!\P8"N7AJ8 ZY7FRD1",Y3".3:A[;.G])^467 M":V@S^CP:&:4:3(.TTC3:;N%.!0A#/EF\P1@1DHS&8=FI-W,[I13^"I_QW!D M3<-A&)D4\YL+C?CBRK47TQ#SLH[K_AA2JLDX5"//NED3O]0$DS&(1B9 M#/.XGD?_SSJ5VW=O.X248+(#"^8Q/%6V,ZAJ\M +X1DEF(Q#,$/I M;7:*,2G39!RFV9LWBD]/;HXQ*=-D'*;YD#QVB*6//V-,RC09AVF&LD@UP45.4A11+F;.3:^Q]-"D)J6,NJJDSC$E) M2'%(:$CIZAQC4A)2QUQ8TUA"FI*0/N;"FI88DY*0/MK"FO@T]3@KUI2$-(>$ M]F.F/ Y&TH42)^^:W-/AD-!'S.TQQJ0DI#DD-(2IL80T)2'- M(:&AK%CC4DA3%M(<%AK$Q!;2E(4TAX4&,;&%-&4AS6&A@1JC'S<-92%SO%(H MG<.8E(4,AX6&, TNA0QE(<-2"@U4; :_5F H"QF64F@($Y="AK*082F%AC![ MKQ:0[Q:PE$(?Z]^/3C>4A:E(4LBX5V,4_$ MW6+A\[:'2;[CQF*A??MKNVFQI2QD.PN-N\;Q^K* J%OYX@$N$>%\[LI\UHCT ML7GM1YNT ;]8E^4MG/NS@M(AG>_ZV+[?>_TO4$L#!!0 ( %5_#DT7K2RZ M.0( %XH : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%VDMNVS 4 MA>&M&%I :-X'DQ1Q1IUDVG8#@DT_$%L21!5-=E_5DZI HM.!<321(+N>F;*KC,'1?0BC;8[[4Y:[MPV5?^RB]7J1]T?\K"IPMLY_&K[UW+,>2CA M^A/OQ@7&O[QW^7^6;_?[TS9_;;<_+[D9/JCXNT 5/@Z2^2"A!^E\D-*#;#[( MZ$$^'^3TH#0?E.A!]_-!]_2@A_F@!WK0XWS0(STHKH&,:WX2PIJO=01<1[[7 M$8 =^6)'0';DFQT!VI&O=@1L1[[;$< =^7)'0'?DVQT!WI&OMP"]A:^W +UE M@7=M]++-UUN WL+76X#>PM=;@-["UUN WL+76X#>PM=;@-["UUN WL+76X'> MRM=;@=[*UUN!WKK 7@G:+.'KK4!OY>NM0&_EZZU ;^7KK4!OY>NM0&_EZZU M;^7K;4!OX^MM0&_CZVU ;^/K;4!O6V"O&VUV\_4VH+?Q]3:@M_'U-J"W\?4V MH+?Q]3:@M_'U=J"W\_5VH+?S]7:@M_/U=J"W\_5VH+B:]W GHGOMX)Z)WX>B>@=^+KG8#>B:]W GJG M!JG MQX$F2@_C*CE'\#KU3T285I3GWU!+ P04 " !5?PY-<"V0'/P! "A M)P $P %M#;VYT96YT7U1Y<&5S72YX;6S-VLM.XS 4!N!7J;)%C>LK%U$V MP'8&:7@!DYPV49/8L@V4MQ\G7"10D8IHI7_3-#G..7]2ZUOU\O[%4YQM^VZ( MRZ))R5\P%JN&>AM+YVG(E94+O4WY-*R9M]7&KHF)Q<*PR@V)AC1/8X_BZO*& M5O:Q2[/KU^MCZV5AO>_:RJ;6#>QIJ+\TG;\U+ -UTYK8M#Z>Y 7%[':;N\1\ M;5GD:BS8'A.^WCB>Y_O^/E$(;4T_BN96J[:BVE6/?;ZEC#Z0K6-#E/JNC(T- M5/]+H1W6;WGO;$A_;)\;LVW'/BTHCY3DE+<%[1HU%5X_^:\& MON^&R@6:^Y"K(;4['B]'NLO5R,:%AWQ$&K=.3?5>PW/KX_VPSRYLIN^[7OA' M,;+I\+NW?K@< B2'!,FA0')HD!P&),SZ9]Y5_\!4$L! A0# M% @ 57\.31\CSP/ $P( L ( ! %]R96QS M+RYR96QS4$L! A0#% @ 57\.36;S"V"" L0 ! M ( !Z0 &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4 " !5?PY-VB3&^/ M K @ $0 @ &9 0 9&]C4')O<',O8V]R92YX;6Q02P$" M% ,4 " !5?PY-F5R<(Q & "<)P $P @ &X @ >&PO M=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( %5_#DW0RMI3C ( $<) 8 M " ?D( !X;"]W;W)K&PO M=V]R:W-H965T&UL4$L! A0#% @ 57\.39Z_Z/C2 0 MK00 !@ ( !/1 'AL+W=O$0 & @ %N%@ >&PO=V]R:W-H965T&UL4$L! A0#% @ 57\.3?[9FPZC! 6A8 !@ M ( !91H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 57\.35+T].NR 0 T@, !@ ( !$B, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 57\. M34SM82^V 0 T@, !D ( !KBP 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 57\.36ON)R.V 0 T@, M !D ( !=C( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 57\.3: CDN^V 0 T@, !D M ( !/3@ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 57\.34H_M9RW 0 T@, !D ( !!#X 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 57\.3=W8 M@5"X 0 T@, !D ( !RT, 'AL+W=O&PO=V]R:W-H965T&PO M=V]R:W-H965T&UL4$L! A0#% @ 57\.35LL??*W 0 T@, !D ( ! M7T\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 57\.3>*]59"T 0 T@, !D ( !-54 'AL+W=OAL" #&PO=V]R:W-H965T&UL4$L! A0#% @ 57\.35ZR&DK; 0 = 0 !D M ( !@F$ 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 57\.39*V,01) @ $ < !D ( !<&@ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M57\.3;[F%?BX @ APD !D ( !\6\ 'AL+W=O"0 &0 M @ '@<@ >&PO=V]R:W-H965T&UL4$L! A0#% @ 57\.3>.;(/F] 0 MU@, !D ( !;G@ 'AL+W=O@ >&PO=V]R:W-H965T-\ !X;"]W;W)K&UL4$L! A0#% @ 57\.31?\]2]U @ [ < !D M ( !HW\ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 57\.30Q_YVN4 0 '@, !D ( !"(@ 'AL M+W=O&PO=V]R:W-H965T+ !X;"]W;W)K&UL4$L! A0#% @ 57\. M3:4QRR2A 0 BP, !D ( ! (X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 57\.38D-W/N# @ '0D M !D ( !(Y@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 57\.3:K]YII* P \ T !D M ( !UZ$ 'AL+W=O&PO=V]R:W-H965T MK !X;"]W;W)K&UL4$L! A0# M% @ 57\.30Z)M?A6* &UL4$L! A0#% @ 57\.3>VAJ6,O @ ? D T M ( !RM4 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL M4$L! A0#% @ 57\.31>M++HY @ 7B@ !H ( !/=T M 'AL+U]R96QS+W=O XML 80 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 81 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 208 201 1 false 64 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.cenbiotechinc.com/20180630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.cenbiotechinc.com/20180630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.cenbiotechinc.com/20180630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.cenbiotechinc.com/20180630/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) Sheet http://www.cenbiotechinc.com/20180630/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.cenbiotechinc.com/20180630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies Note 1 - Basis of Presentation and Summary of Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Going Concern Uncertainty / Management Plans Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-2-going-concern-uncertainty-management-plans Note 2 - Going Concern Uncertainty / Management Plans Notes 8 false false R9.htm 008 - Disclosure - Note 3 - New Accounting Standards Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-3-new-accounting-standards Note 3 - New Accounting Standards Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Property, Plant and Improvements, Net Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-4-property-plant-and-improvements-net Note 4 - Property, Plant and Improvements, Net Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Advances to CEN Biotech Ukraine Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-5-advances-to-cen-biotech-ukraine Note 5 - Advances to CEN Biotech Ukraine Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Intangible Assets Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-6-intangible-assets Note 6 - Intangible Assets Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Loans Payable Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-7-loans-payable Note 7 - Loans Payable Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Loans Payable - Related Parties Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-8-loans-payable-related-parties Note 8 - Loans Payable - Related Parties Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Convertible Notes Notes http://www.cenbiotechinc.com/20180630/role/statement-note-9-convertible-notes Note 9 - Convertible Notes Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Convertible Notes - Related Parties Notes http://www.cenbiotechinc.com/20180630/role/statement-note-10-convertible-notes-related-parties Note 10 - Convertible Notes - Related Parties Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Income Taxes Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-11-income-taxes Note 11 - Income Taxes Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Shareholders' Deficit Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-12-shareholders-deficit Note 12 - Shareholders' Deficit Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Related Party Transactions Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-13-related-party-transactions Note 13 - Related Party Transactions Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Stock Based Compensation Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-14-stock-based-compensation Note 14 - Stock Based Compensation Notes 20 false false R21.htm 020 - Disclosure - Note 15 - Net Loss Per Share Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-15-net-loss-per-share Note 15 - Net Loss Per Share Notes 21 false false R22.htm 021 - Disclosure - Note 16 - Contingency Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-16-contingency Note 16 - Contingency Notes 22 false false R23.htm 022 - Document - Note 17 - Fair Value Disclosures Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-17-fair-value-disclosures Note 17 - Fair Value Disclosures Uncategorized 23 false false R24.htm 023 - Disclosure - Note 18 - Restatement Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-18-restatement Note 18 - Restatement Uncategorized 24 false false R25.htm 024 - Disclosure - Note 19 - Subsequent Event Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-19-subsequent-event Note 19 - Subsequent Event Uncategorized 25 false false R26.htm 025 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.cenbiotechinc.com/20180630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Uncategorized 26 false false R27.htm 026 - Disclosure - Note 4 - Property, Plant and Improvements, Net (Tables) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-4-property-plant-and-improvements-net-tables Note 4 - Property, Plant and Improvements, Net (Tables) Uncategorized 27 false false R28.htm 027 - Disclosure - Note 6 - Intangible Assets (Tables) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-6-intangible-assets-tables Note 6 - Intangible Assets (Tables) Uncategorized 28 false false R29.htm 028 - Disclosure - Note 7 - Loans Payable (Tables) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-7-loans-payable-tables Note 7 - Loans Payable (Tables) Uncategorized 29 false false R30.htm 029 - Disclosure - Note 8 - Loans Payable - Related Parties (Tables) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-8-loans-payable-related-parties-tables Note 8 - Loans Payable - Related Parties (Tables) Uncategorized 30 false false R31.htm 030 - Disclosure - Note 9 - Convertible Notes (Tables) Notes http://www.cenbiotechinc.com/20180630/role/statement-note-9-convertible-notes-tables Note 9 - Convertible Notes (Tables) Uncategorized 31 false false R32.htm 031 - Disclosure - Note 10 - Convertible Notes - Related Parties (Tables) Notes http://www.cenbiotechinc.com/20180630/role/statement-note-10-convertible-notes-related-parties-tables Note 10 - Convertible Notes - Related Parties (Tables) Uncategorized 32 false false R33.htm 032 - Disclosure - Note 11 - Income Taxes (Tables) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-11-income-taxes-tables Note 11 - Income Taxes (Tables) Uncategorized 33 false false R34.htm 033 - Disclosure - Note 14 - Stock Based Compensation (Tables) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-14-stock-based-compensation-tables Note 14 - Stock Based Compensation (Tables) Uncategorized 34 false false R35.htm 034 - Disclosure - Note 15 - Net Loss Per Share (Tables) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-15-net-loss-per-share-tables Note 15 - Net Loss Per Share (Tables) Uncategorized 35 false false R36.htm 035 - Disclosure - Note 17 - Fair Value Disclosures (Tables) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-17-fair-value-disclosures-tables Note 17 - Fair Value Disclosures (Tables) Uncategorized 36 false false R37.htm 036 - Disclosure - Note 18 - Restatement (Tables) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-18-restatement-tables Note 18 - Restatement (Tables) Uncategorized 37 false false R38.htm 037 - Disclosure - Note 2 - Going Concern Uncertainty / Management Plans (Details Textual) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-2-going-concern-uncertainty-management-plans-details-textual Note 2 - Going Concern Uncertainty / Management Plans (Details Textual) Uncategorized 38 false false R39.htm 038 - Disclosure - Note 4 - Property, Plant and Improvements, Net (Details Textual) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-4-property-plant-and-improvements-net-details-textual Note 4 - Property, Plant and Improvements, Net (Details Textual) Uncategorized 39 false false R40.htm 039 - Disclosure - Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) Uncategorized 40 false false R41.htm 040 - Disclosure - Note 5 - Advances to CEN Biotech Ukraine (Details Textual) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-5-advances-to-cen-biotech-ukraine-details-textual Note 5 - Advances to CEN Biotech Ukraine (Details Textual) Uncategorized 41 false false R42.htm 041 - Disclosure - Note 6 - Intangible Assets (Details Textual) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-6-intangible-assets-details-textual Note 6 - Intangible Assets (Details Textual) Uncategorized 42 false false R43.htm 042 - Disclosure - Note 6 - Intangible Assets - Intangible Assets (Details) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-6-intangible-assets-intangible-assets-details Note 6 - Intangible Assets - Intangible Assets (Details) Uncategorized 43 false false R44.htm 043 - Disclosure - Note 7 - Loans Payable (Details Textual) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-7-loans-payable-details-textual Note 7 - Loans Payable (Details Textual) Uncategorized 44 false false R45.htm 044 - Disclosure - Note 7 - Loans Payable - Loans Payable (Details) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-7-loans-payable-loans-payable-details Note 7 - Loans Payable - Loans Payable (Details) Uncategorized 45 false false R46.htm 045 - Disclosure - Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-7-loans-payable-loans-payable-details-parentheticals Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals) Uncategorized 46 false false R47.htm 046 - Disclosure - Note 8 - Loans Payable - Related Parties (Details Textual) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-8-loans-payable-related-parties-details-textual Note 8 - Loans Payable - Related Parties (Details Textual) Uncategorized 47 false false R48.htm 047 - Disclosure - Note 8 - Loans Payable - Related Parties - Loans Payable to Related Parties (Details) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-8-loans-payable-related-parties-loans-payable-to-related-parties-details Note 8 - Loans Payable - Related Parties - Loans Payable to Related Parties (Details) Uncategorized 48 false false R49.htm 048 - Disclosure - Note 8 - Loans Payable - Related Parties - Loans Payable to Related Parties (Details) (Parentheticals) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-8-loans-payable-related-parties-loans-payable-to-related-parties-details-parentheticals Note 8 - Loans Payable - Related Parties - Loans Payable to Related Parties (Details) (Parentheticals) Uncategorized 49 false false R50.htm 049 - Disclosure - Note 9 - Convertible Notes (Details Textual) Notes http://www.cenbiotechinc.com/20180630/role/statement-note-9-convertible-notes-details-textual Note 9 - Convertible Notes (Details Textual) Uncategorized 50 false false R51.htm 050 - Disclosure - Note 9 - Convertible Notes - Convertible Notes (Details) Notes http://www.cenbiotechinc.com/20180630/role/statement-note-9-convertible-notes-convertible-notes-details Note 9 - Convertible Notes - Convertible Notes (Details) Uncategorized 51 false false R52.htm 051 - Disclosure - Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals) Notes http://www.cenbiotechinc.com/20180630/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals) Uncategorized 52 false false R53.htm 052 - Disclosure - Note 10 - Convertible Notes - Related Parties (Details Textual) Notes http://www.cenbiotechinc.com/20180630/role/statement-note-10-convertible-notes-related-parties-details-textual Note 10 - Convertible Notes - Related Parties (Details Textual) Uncategorized 53 false false R54.htm 053 - Disclosure - Note 10 - Convertible Notes - Related Parties - Convertible Notes Payable to Related Parties (Details) Notes http://www.cenbiotechinc.com/20180630/role/statement-note-10-convertible-notes-related-parties-convertible-notes-payable-to-related-parties-details Note 10 - Convertible Notes - Related Parties - Convertible Notes Payable to Related Parties (Details) Uncategorized 54 false false R55.htm 054 - Disclosure - Note 10 - Convertible Notes - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals) Notes http://www.cenbiotechinc.com/20180630/role/statement-note-10-convertible-notes-related-parties-convertible-notes-payable-to-related-parties-details-parentheticals Note 10 - Convertible Notes - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals) Uncategorized 55 false false R56.htm 055 - Disclosure - Note 11 - Income Taxes (Details Textual) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-11-income-taxes-details-textual Note 11 - Income Taxes (Details Textual) Uncategorized 56 false false R57.htm 056 - Disclosure - Note 11 - Income Taxes - Reconciliation of Effective Tax Rate (Details) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-11-income-taxes-reconciliation-of-effective-tax-rate-details Note 11 - Income Taxes - Reconciliation of Effective Tax Rate (Details) Uncategorized 57 false false R58.htm 057 - Disclosure - Note 11 - Income Taxes - Deferred Tax Assets (Details) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-11-income-taxes-deferred-tax-assets-details Note 11 - Income Taxes - Deferred Tax Assets (Details) Uncategorized 58 false false R59.htm 058 - Disclosure - Note 12 - Shareholders' Deficit (Details Textual) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-12-shareholders-deficit-details-textual Note 12 - Shareholders' Deficit (Details Textual) Uncategorized 59 false false R60.htm 059 - Disclosure - Note 13 - Related Party Transactions (Details Textual) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-13-related-party-transactions-details-textual Note 13 - Related Party Transactions (Details Textual) Uncategorized 60 false false R61.htm 060 - Disclosure - Note 14 - Stock Based Compensation (Details Textual) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-14-stock-based-compensation-details-textual Note 14 - Stock Based Compensation (Details Textual) Uncategorized 61 false false R62.htm 061 - Disclosure - Note 14 - Stock Based Compensation - Restricted Stock Award Activity (Details) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-14-stock-based-compensation-restricted-stock-award-activity-details Note 14 - Stock Based Compensation - Restricted Stock Award Activity (Details) Uncategorized 62 false false R63.htm 062 - Disclosure - Note 15 - Net Loss Per Share - Antidilutive Securities (Details) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-15-net-loss-per-share-antidilutive-securities-details Note 15 - Net Loss Per Share - Antidilutive Securities (Details) Uncategorized 63 false false R64.htm 063 - Disclosure - Note 17 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-17-fair-value-disclosures-fair-value-of-financial-instruments-details Note 17 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) Uncategorized 64 false false R65.htm 064 - Disclosure - Note 18 - Restatement (Details Textual) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-18-restatement-details-textual Note 18 - Restatement (Details Textual) Uncategorized 65 false false R66.htm 065 - Disclosure - Note 18 - Restatement - Effect on Previously Issued Consolidated Financial Statements (Details) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-18-restatement-effect-on-previously-issued-consolidated-financial-statements-details Note 18 - Restatement - Effect on Previously Issued Consolidated Financial Statements (Details) Uncategorized 66 false false R67.htm 066 - Disclosure - Note 19 - Subsequent Event (Details Textual) Sheet http://www.cenbiotechinc.com/20180630/role/statement-note-19-subsequent-event-details-textual Note 19 - Subsequent Event (Details Textual) Uncategorized 67 false false All Reports Book All Reports cenb-20180630.xml cenb-20180630.xsd cenb-20180630_cal.xml cenb-20180630_def.xml cenb-20180630_lab.xml cenb-20180630_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 85 0001437749-18-015574-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-18-015574-xbrl.zip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end